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Abstract 
 
Klebsiella pneumoniae is an opportunistic pathogenic bacterial species. It is commonly associated 
with acquired hospital infections where it mostly causes pneumonia and urinary tract infection. 
Recently emergence of multidrug resistant K. pneumoniae has created a big problem in treatment of 
these infections which is reflected in increasing mortality. Several virulence factors contribute to the 
pathogenicity of K. pneumoniae. Among them, type 3 fimbriae mediate bacterial adherence to host 
surfaces thereby helping to maintain the infection. Type 3 fimbriae are also involved in formation of 
biofilm which is a problem in patients with indwelling devices. Biofilm is very difficult to treat 
because of its resistance toward both antibiotics and host immune response. However the specific 
receptor of type 3 fimbriae remains still unknown. Therefore, identification would provide valuable 
information regarding the binding of type 3 fimbria to the host. This would help in developing new 
antimicrobial agents, which could be used for treatment of K. pneumoniae infections.  
The aim of the thesis was to characterize the fimbrial adhesin of type 3 fimbria in K. pneumoniae in 
an attempt to identify the receptor of the fimbria. The fimbrial adhesin MrkD was expressed in E. 
coli BL21(DE3) cells and purified with Immobilizing Metal-ion Affinity Chromatography (IMAC). 
However, refolding of the protein after IMAC purification was not possible.  
Instead a type 3 fimbriae expressing E. coli strain was used to perform binding assays in order to 
examine the binding of MrkD to a variety of different ligands. MrkD was binding to all tested 
ligands with exception of type 1 fimbriae from E. coli, which is remarkable. The binding of MrkD 
to type 1 fimbriae were investigated further by examining the binding to different type 1 fimbriae 
variants. There was a difference in binding of MrkD to the different type 1 fimbria variants. To 
examine whether the structure of type 1 fimbriae was responsible for the reduced binding potency 
of MrkD, the fimbriae were treated with various agents that can potentially incur structural changes 
upon them, such as HCl, SDS and glycerol. Glycerol-treatment of type 1 fimbriae did not influence 
MrkD binding to the fimbria. However, an increase in MrkD binding was seen to HCl- and SDS-
treated fimbriae. SDS-PAGE showed that HCl-treated fimbriae were depolymerized into 
monomeric subunit. Interestingly, the SDS-PAGE also showed that SDS did not depolymerize the 
fimbriae. Additionally, transmission electron microscopy of SDS-treated type 1 fimbriae showed no 
structural change of the fimbriae. Though, SDS has been shown to be bind to proteins and increase 
the negatively charge of the proteins. Therefore the increase in MrkD binding to SDS-treated 
fimbriae might be due to electrostatic interactions caused by the binding of negatively charged SDS 
to type 1 fimbriae.  
To examine whether the blocking potency toward MrkD binding was unique to type 1 fimbria, the 
binding of MrkD was examined on CFA/I and CS17 pili. It was found that CS17 pili had similar 
blocking potency to MrkD binding as type 1 fimbriae. Meanwhile CFA/I pili showed no blocking 
of MrkD binding.  
It seems that MrkD binding to the ligands is caused by electrostatic interactions. However, a lot still 
remains unknown about type 3 fimbriae and the receptor.  
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Abstract (Danish) 
 
Klebsiella pneumoniae er en opportunistisk patogen bakterie. Den er oftest associeret med 
hospitalserhvervet infektioner, hvor den giver lungebetændelse og urinvejsinfektioner. Den nylige 
forekomst af multiresistente K. pneumoniae har medført et stort behandlingsmæssigt problem af 
disse infektioner, som kan ses ved en stigende mortalitetsrate. K. pneumoniae har flere virulens 
faktorer, der bidrager til dens patogenitet. En af virulens faktorerne er type 3 fimbriae, som gør det 
muligt for K. pneumoniae at binde til værten og vedholde infektionen. Type 3 fimbriae bliver også 
brugt under dannelsen af biofilm, hvilket er et stort problem hos patienter med katetre. Biofilm er 
nemlig meget vanskelig at behandle, da den både er resistent over for antibiotika og 
immunresponset i værten. Den præcise receptor for type 3 fimbriae er dog stadig ikke identificeret. 
Identifikationen af denne receptor ville kunne bidrage til udviklingen af nye antimikrobielle midler, 
der kunne bruges til behandling af infektioner forårsaget af K. pneumoniae.  
Formålet med dette studie var at karakterisere adhæsinet MrkD på type 3 fimbriae hos K. 
pneumoniae for at forsøge, at identificere receptoren for type 3 fimbriae. Først blev det forsøgt at 
udtrykke og oprense MrkD adhæsinet. Dette blev gjort ved at udtrykke adhæsinet i E. coli 
BL21(de3) celler og efterfølgende oprense det udtrykte protein ved hjælp af Metal-ion 
affinitetskromatografi (IMAC). Efter proteinoprensning med IMAC skulle MrkD proteinet re-
foldes, hvilket ikke var muligt efter adskillige forsøg. I stedet blev det derfor forsøgt at karakterisere 
MrkD ved at anvende en E. coli stamme, der udtrykte type 3 fimbriae. Denne stamme blev brugt til 
at teste bindingen af MrkD til forskellige ligander. Det viste sig, at MrkD bandt til alle de ligander, 
der blev testet, på nær type 1 fimbriae fra E. coli. Dette var interessant da MrkD havde bundet til 
alle andre ligander, der var blevet testet. Den nedsatte binding af MrkD til type 1 fimbriae blev 
derfor undersøgt yderligere ved at anvende forskellige type 1 fimbriae varianter. Det viste sig, at der 
var en forskel i binding af MrkD til de forskellige varianter af type 1 fimbriae. For at finde ud af om 
det var strukturen på type 1 fimbriae, der var årsag til denne forskel i binding af MrkD, blev 
strukturen af type 1 fimbriae forsøgt ændret ved at tilsætte HCl, SDS og glycerol til fimbriaerne. 
Der var ikke nogen forskel i binding af MrkD til glycerol-behandlingen type 1 fimbriae. Til 
gengæld var binding af MrkD til type 1 fimbriaerne øget, når de var behandlet med HCl og SDS. 
Ved SDS-PAGE analyse viste det sig, at HCl depolymeriserede type 1 fimbriae til enkelte subunits, 
hvilket SDS ikke gjorde. Ved transmission elektron mikroskopi (TEM) af SDS-behandlede type 1 
fimbriae viste det sig, at SDS ikke havde nogen indvirkning på strukturen af fimbriaerne. Det var 
dog tidligere blevet vist, at SDS kan binde til proteiner og øge den negative ladning af proteinerne. 
Derfor kan stigningen i binding af MrkD til SDS-behandlede fimbriaer muligvis skyldes 
elektrostatisk interaktion, på grund af den negative ladning som SDS giver fimbriaerne. 
For at undersøge om blokeringen af MrkD binding var unik for type 1 fimbria, blev bindingen af 
MrkD også undersøgt til CFA/I og CS17 pili. Det viste sig, at CS17 pili havde samme evne til at 
blokere binding af MrkD som type 1 fimbriae. Derimod viste CFA/I pili ingen blokering af MrkD 
bindingen.  
Det ser ud til, at bindingen af MrkD til de forskellige ligander skyldes elektrostatiske interaktioner. 
Dog er der stadig meget, der ikke vides omkring binding af type 3 fimbriae til dens receptor.   
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Abbreviations 
 
Abbreviation Description 
CFA/I pili Colonization Factor Antigen pili 
CPS Capsule polysaccharide 
CS17 pili Coli surface antigen pili 
E. coli Escherichia coli 
ELISA Enzyme-Linked Immunosorbent Assay 
ESBL Extended-Spectrum β-Lactamase  
FimA Major subunit of type 1 fimbria 
FimH Adhesin of type 1 fimbria 
FPLC Fast Protein Liquid Chromatography 
HRP Horseradish Peroxidase 
IMAC Immobilized Metal ion Affinity Chromatography 
kDa Kilo Dalton 
K. pneumoniae Klebsiella pneumoniae 
LB Luria Bertani broth 
LPS Lipidpolysaccharide 
MDR Multi-drug resistance 
mrkA The gene the encodes for the major subunit MrkA of type 3 fimbria 
mrkB The gene the encodes for the usher MrkB of type 3 fimbria 
mrkC The gene the encodes for the chaperon MrkC of type 3 fimbria 
mrkD The gene the encodes for the adhesin MrkD of type 3 fimbria 
mrkF The gene the encodes for the anchor protein MrkF of type 3 fimbria 
OD Optical density 
PBS Phosphate buffered saline 
PCR Polymerase Chain Reaction 
RPC Reverse-Phase Chromatography  
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
TEM Transmission electron microscopy 
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Aim 
 
The aim of this thesis was to characterize the fimbrial adhesin MrkD of type 3 fimbria in K. 
pneumoniae in an attempt to identify the receptor of the adhesin. The identification of the receptor 
would lead to valuable information about the adherence of K. pneumoniae during infection, which 
could contribute to the developing of new antimicrobial agents and vaccines targeting K. 
pneumoniae. 
 
To achieve this goal of characterization of MrkD different approaches were explored. One approach 
was to express and purify the MrkD. MrkD protein was expressed in E. coli BL21(DE3) using three 
constructs containing mrkD gene after induction with IPTG. Only one out of three construct showed 
presence of expressed protein (in inclusion bodies), which was subsequently purified by IMAC, and 
its refolding was attempted dialysis. However refolding of the protein was not possible. Therefore, 
next approach to identify the receptor of MrkD was to study binding properties of an E.coli strain 
which expressed type 3 fimbriae. The binding of MrkD was examined in ELISA assays. To verify 
the results from the ELISA assays, transmission electron microscopy was performed.     
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Introduction 
 
Since 2010 the level of hospital acquired infections has been on a constant level of approximately 7-
8 % in Denmark [57]. Hospital acquired infections are caused by microorganisms and affects 
patients as a result of hospitalization. The most frequently hospital acquired infections are urinary 
tract infections (UTI), sepsis, respiratory tract infections and infection of operation wounds. The 
infections can occur through the classical infection routes; airborne, direct contact and indirect 
contact. The severity of hospital acquired infections is varying but in most cases it prolongs the 
hospitalization time. Some of the infections can have a deadly outcome [58].   
 
Klebsiella pneumoniae is a Gram negative rod-shaped bacteria belonging to the bacterial family 
Enterobacteriaceae. It is becoming a more prominent pathogen worldwide especially in nosocomial 
infections. It is estimated that K. pneumoniae is responsible for up to 8 % of all nosocomial 
infections. The infections caused by K. pneumoniae are mostly urinary tract and respiratory tract 
infections in individuals with indwelling devices. Additionally, K. pneumoniae  is also the causative 
agent of cause wound infections and sepsis [1].     
 
The initial step of infection for many pathogenic bacteria is adhesion to the host tissues. The 
adhesion is a critical step in the infection and has to be strong enough to overcome the defense 
mechanisms of the host such as clearance of urethra and the respiratory tract [1]. To overcome these 
defense mechanisms bacterial cells developed fimbriae which are flexible appendages on the 
bacterial surface used for adhesion to host cells or tissue [2]. K. pneumoniae has different types of 
fimbriae but the most pronounced is type 3 fimbriae. Type 3 fimbriae are both used for adhesion to 
the host tissue and for biofilm formation. However, the specific receptor of the fimbriae has still not 
been identified [3].      
 
Hospital acquired infections represent a significant problem and a financial burden. In US alone it is 
estimated that 5-6 billion USD is spent on the management of these infections. Half of hospital 
acquired infections are associated with the use of medical devices such as urinary and intravascular 
catheters.  It is the formation of biofilm on the catheters that enables the bacteria to evade host 
defenses and avoid the hydrodynamic forces [1]. Therefore the identification of the receptor of type 
3 fimbriae will help in developing surfaces to which the fimbriae could not adhere to.  
 
At the same time there are emerging worldwide antibiotic-resistant strains of K. pneumoniae. These 
strains have become a big concern because antibiotic treatment has no effect [1]. This is another 
reason why identification of the type 3 fimbrial receptor is so important. If the receptor is identified 
it will contribute to developing new approaches to treat and prevent the infection. 
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Epidemiology  
 
Taxonomy 
 
The genus Klebsiella was named to honor the German microbiologist Edwin Klebs in 1885, but it 
was recognized as a pathogen by Friedlander in 1882. The current nomenclature is that Klebsiella is 
a genus belonging to the family of Entrobacteriaceae. Klebsiella is a non-motile, Gram negative 
rod-shaped bacteria. The taxonomic history of Klebsiella has been turbulent since its discovery in 
the late nineteenth century. Though, today the species that are considered to belong to the Klebsiella 
genus are K. pneumoniae, K. oxytoca and K. variicola. Among them, the most clinically important 
species are K. pneumoniae and K. oxytoca [2, 4-6]. 
   
Habitat/reservoir 
 
Klebsiella spp. are found everywhere in nature. In the environment Klebsiella spp. is mostly found 
in water, soil and on plants. However, Klebsiella spp. is also found on mucosal surfaces of 
mammals e.g. humans, horses or swine [5, 7].  K. pneumoniae is carried in the intestinal flora in 5-
38 % of healthy individuals as a part of the normal flora and approximately 1-6 % carries it in the 
nasopharynx [1].   
 
Infection site and prevalence 
 
K. pneumoniae is an opportunistic pathogen which preferentially targets immunosuppressed 
individuals, where it can cause urinary tract infection, pneumoniae and septicemia [8]. It is 
estimated that K. pneumoniae is responsible for up to 8-10 % of all bacterial nosocomial infections. 
Therefore K. pneumoniae is becoming a prominent nosocomial pathogen worldwide [1, 8]. 
Nosocomial infections tend to be chronic due to two major reasons: biofilm formation that protects 
the bacteria from the immune response and multi-drug resistance (MDR) that makes it very difficult 
to treat with antibiotics [6]. K. pneumoniae has both the ability to form biofilm and it is resistant 
toward many antibiotics which gives it an advantage during infections [1].  
 
Mainly urinary and respiratory tract infections that are caused by K. pneumoniae, and it is usually in 
individuals with indwelling devices (Table 1). However K. pneumoniae has also been implicated in 
other infection, e.g. bacteremia, septicemia and surgical wound infections [1].  
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Table 1: Distribution of hospital-acquired infections caused by Klebsiella spp. Modified [5]. 
Infection % of infection caused by 
Klebsiella 
Urinary tract infection 6-17 % 
Pneumonia 7-14 % 
Septicemia 4-15 % 
Wound infections 2-4 % 
 
Among nosocomial infections, UTI’s (urinary tract infections) are the most prevalent type of 
infection caused by K. pneumoniae, and 97 % of these infections are associated with indwelling 
devices such as catheters [1]. Another feature of K. pneumoniae is the biofilm formation [3]. 
Biofilm is defined as structured bacterial communities that are enclosed in an exopolysaccharide 
matrix produced by them, which can adhere to abiotic and biological surfaces. The first step in the 
biofilm formation is the association between bacteria and surface or microbes already attached to 
the surface [7]. The biofilm protects the bacteria from hydrodynamic forces such as urine flow, 
against host defense and antibiotics [9]. The biofilm formed by K. pneumoniae, type 3 fimbriae 
have been shown to be the major contributor [10].  
 
It has also been reported that K. pneumoniae is the primary pathogen in pyogenic liver abscesses in 
patients with diabetes mellitus in Taiwan. There is a higher incident rate of pyogenic liver abscesses 
in Taiwan (17.6/100,000 in 2004) compared to the incident rate in Denmark (1/100,000). However 
the mechanism behind the increased risk of liver abscesses caused by K. pneumoniae is still not 
found. [11]. 
 
K. pneumonia can also cause meningitis in both newborns and adults. Menigitis caused by K. 
pneumoniae is most frequently seen in patients with diabetes mellitus, but has also been shown to 
be associated with septicemia or neurosurgical procedures [12, 13].  
 
Resistance to antibiotics 
 
K. pneumoniae has become a very important clinical microorganism due to its tendency to develop 
antibiotic resistance, which in turn can have fatal outcomes [14]. All K. pneumoniae strains contain 
plasmid-encoded penicillin resistance [15]. In addition, many strains of Klebsiella spp. have also 
acquired plasmid-encoded Extended-Spectrum β-Lactamases (ESBL), which provides resistance to 
cephalosporins of later generations. These strains are associated with more severe clinical outcomes 
following infections [1, 14, 16]. ESBL resistance is due to the production of the extended-spectrum 
beta-lactamase which is an enzyme that attacks the beta-lactam ring in the antibiotics and renders 
the antibiotics ineffective [16]. Because of the ESBL production in K. pneumoniae these infections 
can not be treated with beta-lactam antibiotics (such as penems and cephalosporins) and must be 
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treated with other antibiotics, e.g. carbapenems, aminoglycosides or fluoroquinolones. However, the 
extensive use of antibiotic has caused a selective pressure which now had led to the emergence of 
multidrug-resistant (MDR) clones of K. pneumoniae [14]. Moreover, the transmission of plasmids 
has also contributed to the spread of resistance between the bacterial species [14, 17]. Now strain of 
K. pneumoniae show resistance towards carbapenem antibiotics which until now have been used to 
treat the ESBL-producing strains [14, 18]. Carbapenem-resistant K. pneumoniae are becoming a big 
problem and nearly 50 % of patients who develop bloodstream infections with such bacteria die 
from the infection [18]. Though, it has been shown that the antibiotic-resistance varies significantly 
with to the region, country and social structure of population, the modern medicine is under serious 
threat from the continued rise of resistant bacteria [14, 18]. 
 
Virulence factors  
 
To infect the host, the invading bacteria must be able to perform a number of tasks, such as 
colonization of the host, growth within the host and escape from or inhibition of the defense 
mechanisms of the host. Like other pathogens, the virulence of K. pneumoniae is both complex and 
diverse. Some of the known virulence factors in K. pneumoniae will be described further (Figure 1).   
 
 
Figure 1: Major virulence factors of K. pneumoniae: adhesion with type 1 and type 3 fimbriae, serum 
resistance, LPS, the capsule and siderophores. Modified from [5]. 
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The pathogenesis of K. pneumoniae infection starts with entry of bacteria into body, e.g. by 
insertion of a catheter. Shortly after the insertion of a catheter, it becomes covered with extracellular 
matrix proteins. The bacterial adherence to the medical devices is essential for the further stage in 
the pathogenesis. Adhesion to and subsequent formation of biofilm on the catheter enables the 
bacteria to evade the host’s defenses and avoid the forces of urine flow. From the catheter the 
bacteria can get access to the bladder which is normally sterile and cause urinary tract infections. 
The catheter can also serves as a reservoir for the spread of the bacteria to the blood stream, which 
leads to systemic disease [1].   
 
Type 1 fimbriae 
 
Type 1 fimbriae are commonly found on bacteria in the family Enterobacteriacea. The fimbriae are 
not conserved genetically between different genera in the family but still share some of the same 
functions. However the ligands targeted differ between the different type 1 fimbriae [5]. In  K. 
pneumoniae the type 1 fimbriae are closely related to type 1 fimbriae expressed by other members 
of the Enterobacteriaceae family [7].   
 
Type 1 fimbriae are thin adhesive appendages on the cell surface anchored in the outer membrane 
of the bacteria. Type 1 fimbriae mainly are composed of repeating FimA structural subunits with 
one adhesive subunit on the tip called FimH [6, 19]. In K. pneumoniae the fimbriae are encoded by 
the gene operon fimBEAICDFGHK. The gene fimK is unique to K. pneumoniae type 1 fimbriae and 
acts as a transcriptional regulator. Type 1 fimbriae in E. coli do not encode the fimK gene [6]. fimA 
encodes the major subunit of the fimbriae. FimF and FimG are minor structural subunits attached to 
FimH protein, which is the adhesin of the fimbria. Both FimB and FimE protein regulate the 
expression of the fimbriae. In K. pneumoniae the function of FimI is unknown, however in E. coli it 
shown to be necessary for the production of the fimbria. Type 1 fimbriae bind to mannose-
containing glycoproteins [5].  
 
Type 3 fimbriae 
 
The type 3 fimbriae are appendages that are approximately 2-4 nm wide and 0.5-2 µm in length and 
were first identified by Duguid and coworkers in 1959. Type 3 fimbriae have helix-like structure 
which gives them flexible and stretchable properties similar to springs. The adhesion itself is 
located on the distal end of the fimbriae, while pilins subunits are assembled into a three-
dimensional helical structure forming the backbone of the fimbriae [3]. 
 
Type 3 fimbriae are primarily seen in the Klebsiella genus, however, not all of the species of this 
genus express type 3 fimbriae [7, 8]. Additionally, type 3 fimbriae are also found in other 
enterobacterial pathogens, such as Enterobacter, Serratia, Proteus and Citrobacter species. It has 
been shown in vitro that type 3 fimbriae play a role in binding to several epithelial cell lines and 
extracellular matrix proteins. However, the exact receptor for type 3 fimbria has still not been 
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identified [8, 20]. In addition, the biofilm formation is also promoted by type 3 fimbriae which is 
important for facilitating evasion of the host defense mechanisms, communication between the 
bacteria and protection against antibiotics [7-9, 20].  
 
The genes encoding type 3 fimbria in K. pneumoniae reside in multiple locations in the genome: on 
the chromosome, on conjugative plasmids and within transposon [9]. The mrk gene cluster 
(mrkABCDF) is comprised of five genes encoding the structural and assembly components of type 3 
fimbriae (Figure 2) [1, 8, 21]. Upstream mkrA gene a putative regulatory gene called mrkE has been 
identified. The mrk gene cluster is similar to other fimbrial operons which belong to the chaperone-
usher family [9].  
 
 
 
Figure 2: Physical map of the mrk gene cluster from K. pneumoniae IA565 which carries the plasmid borne 
gene cluster and from K. pneumoniae MGH78578 which has the chromosomal located gene cluster. Arrows 
indicate the direction of the transcription for each of the genes. Modified from [22].    
 
 
MrkA is the major fimbrial subunit and each subunit is approximately 23 kDa. Type 3 fimbrial 
filament is primarily composed of MrkA, which is polymerized to form a helical fimbrial shaft 
(Figure 3) [7, 20]. The structural stability of the fimbriae is due to the β strands in the C-terminal 
region of MrkA [1, 6]. MrkA also facilitates biofilm formation, however the mechanism is still 
unknown [7].  
 
mrkB encodes the chaperone protein (MrkB) that forms a complex with the fimbrial subunit 
proteins by donor-strand complementation mechanism. This complex is directed to the usher in the 
outer membrane (MrkC), encoded by the gene mrkC. The assembly of the fimbriae is called the 
chaperone/usher pathway which is mediated by addition of subunits to the growing appendages 
(Figure 3). [1, 6]. 
 
MrkD is the adhesin of the fimbria and is located at the tip of the fimbriae (Figure 3). Therefore, the 
binding specificity of type 3 fimbriae is determined by MrkD [1, 6]. MrkD mediates binding to 
extracellular matrix proteins, however the specific receptor has not yet been discovered [20]. It has 
strongly been suggested by homology modeling that MrkD has two domain structure, which is 
comprised of a pilin-anchoring domain that connects the adhesin to the fimbrial shaft, and a lectin 
domain which contains the binding pocket [8]. 
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The function of MrkF is unknown. It may represent a minor fimbrial subunit since MrkF mutants 
retain the ability to produce fimbriae (Figure 3) [1]. However, it has been suggested that MrkF 
functions as an initiator for the growth of the fimbria [13]. In addition, only relatively little is 
known about the regulation of the expression of type 3 fimbriae in K. pneumoniae, but it seems to 
involve cyclic di-GMP pathways [1].  
 
 
 
Figure 3: Genes encoding the type 3 fimbria and the assembly of type 3 fimbria [1].  
 
 
The homology between mrk gene cluster on plasmid and chromosome varies from 60 % to 96 %, 
and mrkD genes are most diverse among other genes. The plasmid-born mrk gene cluster is only 
found in very few isolates of K. pneumoniae, while the chromosomal gene cluster is found in the 
majority of K. pneumoniae isolates [8]. This is quite unusual because the greatest diversity is 
normally seen within the major fimbrial subunit, and not within the adhesin. Though, a study have 
shown that the diversity in the MrkD adhesin is associated with different binding properties [9].   
 
Type 1 and type 3 fimbriae can be distinguished phenotypically based on their abilities to 
agglutinate erythrocytes in the presence of mannose. Type 1 fimbriae do not agglutinate 
erythrocytes in the presence of mannose and thus are called mannose-sensitive. In opposite, type 3 
fimbriae can agglutinate erythrocytes in the presences of mannose and thus are called mannose-
resistant [1, 9, 23].   
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Other fimbriae 
 
In addition to type 1 and type 3 fimbriae K. pneumoniae also possess other fimbriae, e.g. Kpc 
fimbriae and KPF-28 adhesin. The Kpc fimbriae are associated with hypermucoviscous K. 
pneumoniae. They are encoded by the kpcABCD operon. KpcA is the major subunit of the Kpc 
fimbria [6]. 
The KPF-28 adhesin is associated with the binding of K. pneumoniae to the Caco-2 cell line. This 
indicates that it is used for colonization of the mammalian intestine. The KPF-28 adhesin is a long 
and flexible fimbria with a length of 0.5-2 nm and a diameter of 4-5 nm. The gene of KPF-28 
adhesin is located on a transferrable R plasmid [6, 13].  
 
Capsule 
 
The capsule is essential for the virulence of Klebsiella spp. The capsule is composed of a complex 
of acidic polysaccharides (CPS) on the cell surface of the bacteria and acts as a protective shield 
against the defense mechanisms of the host. The CPS is generally composed of repeating subunits 
of three to six sugars and very often uronic acid. The capsul is formed by thick bundles of fibrillous 
structures that cover the bacterial surface (Figure 4). The capsule is so thick that it protects the 
bacteria from phagocytosis and prevents complement of immune system from killing of the 
bacteria. Besides these main functions it has also been described, that the capsule of Klebsiella spp. 
inhibits the differentiation and functionality of macrophages and dendritic cells [5, 6].    
 
 
Figure 4: Cell wall of a Gram negative bacterium. It is composed of a plasma membrane, periplasmic space 
and an outer membrane. The outer membrane is composed of LPS. Besides the cell wall the bacterium can 
also have a capsule of polysaccharides that lies around the bacterial cell wall [59].  
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Lipopolysaccharide  
 
Lipopolysaccharide (LPS) is composed of three parts: lipid A, O-antigen and the core 
polysaccharide (Figure 4). 
 
The lipid A is a hydrophobic anchor in the outer membrane of Gram negative bacteria and is highly 
conserved. Lipid A keeps the LPS bound to the outer membrane and at the same time it acts as an 
endotoxin. The core polysaccharide makes the connection between lipid A and O-antigen. There 
have only been characterized two types of core polysaccharides in K. pneumoniae. The O-antigen 
attached to the core polysaccharide and is composed of a glycan polymer. The O-antigen is the 
outer domain of the LPS and prevents the activating of complement factors by blocking their access 
to the membrane this is also referred to as serum resistance. In K. pneumoniae there have been 
recognized at least nine different O-antigen groups each having high chemical variability from one 
to another. The O-antigen increases the probability of bacteremia [6].   
 
Siderophores 
 
Iron is an essential factor for bacterial growth and for the reason the bacteria must be able to supply 
itself with enough iron to survive. The iron participates in the oxygen and electron transport in the 
bacteria. In the host the amount of free iron is very low because it is bond to intracellular and 
extracellular proteins such as hemoglobin and transferrin. For this reason many bacteria secret 
siderophores which competes with host proteins for taking up iron. The Klebsiella genus produce 
both enterobactin and aerobactin for this purpose [5]. 
 
Other virulence factors 
 
K. pneumoniae also express efflux pumps which contributes not only to the efflux of antibiotic but 
also the efflux of host-derived antimicrobial agents. One of the efflux pumps is AcrAB and another 
is EefABC. AcrAB is associated with multidrug resistance and EefABC is associated with acid 
tolerance [6].       
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Materials and method(s) 
 
 
Table 2: Overview and description of the used strains. 
 
Strain(s) 
 
 
Description 
 
Antibiotic 
resistance 
 
Reference 
 
Klebsiella peumoniae 
 
C3091 Wild type - Struve collection SSI 
C3091 ∆fim ∆mrk Deletion of fim and mrk 
operons of C3091 Wild 
type 
Kanamycin Struve collection SSI 
 
Escherichia coli 
 
BL21(de3) Protein expression - Struve collection SSI 
DH5-α Laboratory strain - Struve collection SSI 
HB101 pmrkABCF  Plasmid containing 
mrkABCF 
Ampicillin Sokurenko collection, 
UW 
STL-327  HB101 strain containing 
plasmid mrkABCF + 
plasmid pGB17 mrkD 
Ampicillin, 
Chloramphenicol 
Sokurenko collection, 
UW 
A188D Single mutation in FimH 
of K12 Wild type 
Ampicillin, 
Chloramphenicol 
Sokurenko collection, 
UW 
K12 Wild type Ampicillin, 
Chloramphenicol 
Sokurenko collection, 
UW 
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Table 3: Shows an overview and description of the used fimbriae. All the fimbriae were from 
Sokurenko collection, UW. 
 
Fimbria name 
 
 
Description 
 
Expression strain 
 
Antibiotic resistance 
 
Type 1 fimbriae from K12 E. coli  with diffrent variants of FimH adesin 
 
K12 Wild type AAEC191A Ampicillin, 
Chloramphenicol 
G79R 
 
Single mutation in 
FimH of K12 Wild 
type 
AAEC191A Ampicillin, 
Chloramphenicol 
K12_F Wild type with 
modified FimH pilin 
domain 
AAEC191A Ampicillin, 
Chloramphenicol 
N135I-F 
 
Single mutation in 
FimH of K12_F 
AAEC191A Ampicillin, 
Chloramphenicol 
Q133N-F 
 
Single mutation in 
FimH of K12_F 
AAEC191A Ampicillin, 
Chloramphenicol 
D54E-F 
 
Single mutation in 
FimH of K12_F 
AAEC191A Ampicillin, 
Chloramphenicol 
Y82A-F 
 
Single mutation in 
FimH of K12_F 
AAEC191A Ampicillin, 
Chloramphenicol 
F1A-F 
 
Single mutation in 
FimH of K12_F 
AAEC191A Ampicillin, 
Chloramphenicol 
 
Type 1 fimbriae from E.coli with different variants of FimA  
 
EcoR36 
 
FimA from EcoR36 AAEC191A Ampicillin, 
Chloramphenicol 
EcoR52 
 
FimA from EcoR52 AAEC191A Ampicillin, 
Chloramphenicol 
EcoR60 
 
FimA from EcoR60 AAEC191A Ampicillin, 
Chloramphenicol 
vt404 
 
Single mutation in 
FimA from K12 
AAEC191A Ampicillin, 
Chloramphenicol 
vt472 
 
Single mutation in 
FimA from EcoR52 (I) 
AAEC191A Ampicillin, 
Chloramphenicol 
vt473 
 
Single mutation in 
FimA from EcoR52 
(II) 
AAEC191A Ampicillin, 
Chloramphenicol 
vt477 
 
Single mutation in 
FimA from EcoR60 
AAEC191A Ampicillin, 
Chloramphenicol 
vt481 
 
Single mutation in 
FimA from 536 
AAEC191A Ampicillin, 
Chloramphenicol 
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CS17 pili variants 
 
WS-E A variant of CS17 pili BL21SI Kanamycin 
LSN-2 A variant of CS17 pili BL21SI Kanamycin 
LSN-3 A variant of CS17 pili BL21SI Kanamycin 
 
CFA/I pili with different variants of the adhesin CfaE 
 
S138A Single mutation in 
CfaE 
BL21SI Kanamycin 
R182A Single mutation in 
CfaE 
BL21SI Kanamycin 
R67A Single mutation in 
CfaE 
BL21SI Kanamycin 
 
Plasmid vector construct(s) 
 
The aim was to make a clone containing the mrkD gene which encodes the adhesin of type 3 
fimbria. The clones were constructed with a Histidine-tag which should be used for purification of 
the expressed protein. During the project two different constructs (pET24d and pET26b) were 
designed and ordered from GenScript, while the pET28a construct was made by PCR amplification 
followed by digestion with restriction enzyme and ligation.  
 
pET24d is a bacterial expression vector consisting of 5037 bp and contains the bacterial resistances 
gene for Kanamycin. The plasmid was ordered from Genscript and designed to contain the whole 
sequence of the mrkD gene from K. pneumoniae including a complemented donor strand from the 
mrkA gene (which is the major pili subunit) and a N-terminal His-tag (Figure 5). The gene was 
inserted at restriction site XhoI/BamHI. 
 
 
 
 
 
 
 
Figure 5: Construct of mrkD with donor strand complementation of mrkA which was cloned into the plasmid 
pET24d. 
 
 
 
DNKQ Linker 6xHis (His-tag) 
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pET28a is a bacterial expression vector consisting of 5369 bp. It contains the bacterial resistance 
gene for kanamycin. The construct was made by PCR amplification followed by restriction enzyme 
digestions and ligation. It was designed to contain the whole sequence of the mrkD gene from K. 
pneumoniae (Figure 6). The gene was inserted at the restriction sites NheI/XhoI which would give 
protein expression with a N-terminal His-tag.  
 
 
 
 
 
 
Figure 6: Construct of mrkD which was cloned into the plasmid pET28a. 
 
pET26b is a bacterial periplasmic expression vector consisting of 5360 bp. It contains a pelB signal 
sequence that moves the protein expression to the periplasm of the bacteria. It also contains the 
bacterial resistance gene for Kanamycin. The plasmid was ordered from Genscript and designed to 
contain a partial sequence of the mrkD gene from K. pneumoniae from amino acid 21-198 including 
a N-terminal His-tag (Figure 7). The gene was inserted at the restriction sites NcoI/BamHI. 
 
 
 
 
 
 
 
Figure 7: Construct of the partial mrkD gene which has been cloned into the plasmid pET26b. 
 
 
  
6xHis (His-tag) 
6xHis (His-tag) 
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The flow chart shows an overview of the experiments performed for the three different mrkD 
constructs pET24d, pET28a and pET26b (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Flow charge over the experiments performed with the three different constructs pET24d, pET28a 
and pET26b.  
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Plasmid purification 
 
Plasmid purification was done for the pET24d + mrkD and for pET26b. Qiagen Plasmid Midi Kit 
was used for the plasmid purification.  
 
The purification of the pET24d + mrkD plasmid was performed before the plasmid was send to 
sequencing to verify that the plasmid contained the mrkD gene.  
 
The purification of pET26b plasmid was done in order to send it to Genscript, which used it to 
create a construct of the plasmid containing the partial mrkD sequence.   
 
The plasmid purification was started by making a 100 mL overnight culture with the strain 
containing the plasmid. In this case the culture was grown overnight at 37oC and 200 RPM. The 
following day the culture was harvest by centrifugation at 6,000 g for 15 minutes and 4oC. The 
pellet was resuspended in 4 mL of QIAGEN Buffer P1. Then 4 mL of QIAGEN Buffer P2 was 
added and mixed thoroughly by invertion 4-6 times and was left for incubation at room temperature 
for 5 minutes. After the incubation 4 mL of QIAGEN Buffer P3 was added to the mixture and 
mixed thoroughly by inverting 4-6 times. Then the mixture was incubated on ice for 15 minutes. 
After the incubation the mixture was centrifuged at >20,000 g for 30 minutes at 4oC. If the 
supernatant was not clear the solution was centrifuged again. The supernatant was saved and the 
pellet discarded. Meanwhile a QIAGEN-tip was prepared by letting 4 mL QIAGEN QBT Buffer 
run through the column. The supernatant was then loaded into the column. When the supernatant 
had run through the column, the column was washed two times with 10 mL of QIAGEN Buffer QC. 
After the wash the DNA was eluted in a clean tube by adding 5 mL QIAGEN Buffer QF to the 
column and letting it run through. The DNA was precipitated by the addition of 3.5 mL isopropanol 
(room temperature) to the eluted DNA. The solution was mixed and centrifuged at >15,000 g for 30 
minutes at 4oC. The supernatant was carefully removed. The DNA pellet was washed with 2 mL of 
70 % ethanol (room temperature) and centrifuged for 10 minutes at >15,000 g at 4oC. Again the 
supernatant was removed carefully. The pellet was air-dried for 5-10 minutes and then dissolved in 
suitable volume of TE-buffer (Appendix 1). The purified plasmid was stored at -20oC. 
 
PCR 
 
The construct of the plasmid pET28a containing the mrkD gene was made by PCR, digestion with 
restriction enzymes and ligation. This was done by Rie Jønsson, SSI.  
  
Since the pET28a construct with mrkD expressed MrkD in inclusion bodies, the signal peptide was 
removed from the construct to see if this would solve the issue. The removal of the signal peptide 
was done by PCR with a forward and a reverse primer containing the restriction site NheI; the 
forward primer (5’-cgcgcgGCTAGCTCCTGTACGCGTCTCTCATC -‘3) amplified downstream of 
the signal peptide, while the reverse primer  
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(5’-cgcgcgGCTAGCGCTAGCCATATGGCTGCCGCGCGGC-´3) amplified upstream of the 
plasmid before the start of the signal peptide (thereby away from the mrkD gene, i.e., an amplicon 
of the entire pET28a mrkD plasmid without the signal peptide). The PCR product was digested with 
xhoI, ligated and transformed into competent dh5α. The correct deletion of the signal peptide was 
verified by PCR which was sent to Sanger sequencing. The PCR product without the signal peptide 
was then transformed into BL21(de3) cells for expression. 
 
When making the PCR, a reaction mix was prepared followed by addition of the DNA into the mix. 
Then the samples were run on a PCR machine with a 30 cycle program. After the PCR reaction, the 
samples were loaded on an agarose E-gel and a picture was taken of the gel to see the result of the 
PCR reaction.  
 
Transformation into E. coli BL21(de3) 
 
Under a transformation DNA is introduced into a cell. The bacteria that are used for the 
transformation have to be apple to take up DNA efficiently these cells are also called competent 
cells. When the DNA is in the competent cells, the cells are called a clone. Each of the three 
plasmids were transformed into the E. coli strain BL21(de3).  
The transformation was started by inoculation of 5 mL LB-media with appropriate antibiotic with 
the transformation strain at incubated it overnight at 37oC. The following day the overnight culture 
was used for inoculation of 50 mL LB-media (1:50) and incubated at 37oC until the OD600 reached 
0.6-0.8. The flask containing the culture was incubated on ice for 15 minutes and then the culture 
was centrifuged for 10 minutes at 4,000-5,000 RPM and 4oC. The supernatant was discarded and 
the pellet was washed three times with ice cold MiliQ water, first time with 50 mL, second time 25 
mL and the last time with 5 mL. The wash was performed by resuspension of the pellet with the 
water and afterwards centrifugation at 4,000-5,000 RPM for 10 minutes at 4oC. Then the pellet was 
resuspended in 200 µl MiliQ water and 50 µl of the suspension was transferred into an 
electroporation cuvette. One sample was made without the plasmid and one sample was made with 
the plasmid by adding 2 µl of the plasmid to the cell suspension in the cuvette. The samples were 
electroporated by using MicroPulser (BIO-RADTM) and it was ensured that the samples did not 
arch. Then 900 µl of SOC media was transferred to each cuvette and mixed well. The mixtures were 
transferred to two Eppendorf tubes and incubated on a heating block for 1-3 hours at 37oC. After 
incubation 200 µl of the mixtures were spread on two LB plates containing kanamycin and 
incubated overnight at 37oC. The colonies formed on the plate should contain the plasmid. 
 
After transformation, the BL21(de3) containing the clones were induced with IPTG to express 
MrkD protein.  
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IPTG induction 
 
The BL21(de3) cells that have been transformed with the plasmid were grown in LB media at 37oC 
and 200 RPM until OD600 was 0.8. The expression of the inserted gene was induced by the addition 
of IPTG to the medium. IPTG is a galactose analog. IPTG binds to the lac repressor and prevents 
the binding of the repressor to the operator; therefore the transcription of his-tagged mrkD is 
initiated.  
  
The condition under IPTG induction was different between the three plasmids. 
 
BL21(de3) cells containing pET24d + mrkD was first induced with either 0.1 mM, 0.5 mM or 1 
mM IPTG at 37oC for three hours to see which concentration yield the highest protein expression. 
Afterwards IPTG induction with 1 mM IPTG at 20oC overnight was also tried.  
Because no difference was seen between the uninduced and induced samples, the BL21(de3) cells 
containing pET24d + mrkD were grown in both 2xYT media, Terific broth media and LB media. 
For each of the three media there were made a 50 mL culture (1:100), which were grown at 37oC 
and 200 RPM until OD600 was 0.8. When OD600 was 0.8 the 50 mL culture from the three media 
was divided into 12 tubes with 4 mL culture in each. Four of the tubes were incubated at 18oC, four 
at 28oC and the last four tubes at 37oC. For each of temperature one tube was left as an uninduced 
control, one tube was induced with 0.1 mM IPTG, one tube with 0.5 mM IPTG and one tube with 1 
mM IPTG. After one hour of IPTG induction 1 mL of the culture in each tubes were taken out and 
put into a 1.5 mL Eppendorf tube. The IPTG induction was continued with the rest of the culture. 
The Eppendorf tubes containing the samples with one hour IPTG induction was centrifuged for 5 
minutes at 6,000 g. The supernatant was removed and the pellet was resuspended in 100 µL 
sonication buffer (Appendix 1). The samples were stored at -20oC. After three hours IPTG 
induction 1 mL of the culture was taken and put into a 1.5 mL Eppendorf tube. The Eppendorf tubes 
containing the three hours IPTG induction samples were centrifuged, resuspended and stored the 
same way as described for the samples with one hour ITPG induction. The remaining culture was 
left for IPTG induction overnight. The following day 1 mL of the culture were taken and put into 
1.5 mL Eppendorf tubes. The procedure was done the same way for the overnight samples as for the 
one and three hours IPTG induction samples.      
Once again no difference was seen between the uninduced and induced sample and for this reason 
IPTG induction was done in MagicMediaTM from Thermo Fisher Scientific. MagicMediaTM was 
inculated with BL21(de3) cells containing pET24d + mrkD and incubated overnight at 37oC and 
200 RPM.  
 
BL21(de3) cells containing pET28a + mrkD was first induced in MagicMediaTM along with the 
BL21(de3) cells containing pET24d + mrkD to see if there was a difference in protein expressing 
between the two plasmids. Cultures of BL21(de3) cells contain construct pET24d and pET28a were 
inoculated in MagicMediaTM and incubated overnight at 37oC and 200 RPM. 
 
Page 26 of 78 
 
The BL21(de3) cells containing the construct pET28a was also induced with 1 mM IPTG in LB 
media at 37oC and 200 RPM for one and three hours. This resulted in formation of inclusion bodies 
for both the construct with and without the signal peptide. The expressed protein was purified from 
the inclusion bodies.  
 
BL21(de3) cells containing pET26b + mrkD was first induced in LB media with 0.1 mM, 0.5 mM 
and 1 mM IPTG for one and three hours and overnight at 37oC and 200 RPM. This was done to see 
which conditions yield the highest protein expression. After IPTG induction the samples was 
centrifuged at 6,000 RPM for five minutes at 4oC. The supernatant was removed and the pellet was 
resuspended in sonication buffer (Appendix 1). The samples were stored at -20oC.  
Because no difference could be seen at 37oC the induction at 18oC and 28oC was tried with 0.1 mM 
IPTG for one and for three hours. After IPTG induction the samples were centrifuged at 6,000 g at 
4oC, the supernatant was removed and the pellet stored at -20oC.  
  
SDS-PAGE analysis 
 
The SDS-polyacrylamide gel electrophoresis is used to monitor the induction and purification of the 
fusion protein mrkD.  
 
When starting a SDS-PAGE analysis the samples are prepared by adding 15 µl of loading buffer to 
15 µl samples and boil it all together for 5 minutes at 100oC.  
In the meantime the gel cassette and Mini-Cell chamber are prepared. The pre-cast gel are removed 
from the pouch and rinsed with deionized water. Then the tape is removed from the bottom of the 
cassette and the comb is pulled out of the cassette gently. The wells are washed with deionized 
water two times and the water is removed by inverting and shaking the gel. The gel cassette is 
placed in the Mini-Cell with the inward of the cassette facing inwards. The gel cassette is put down 
to the bottom of the Mini-Cell chamber and locked into place with a gel tension wedge. The buffer 
chamber is then filled up with Running buffer and is checked for tightness of seal (Appendix 1). If 
the buffer chamber is tight the Mini-Cell chamber is filled with approximately 600 ml of Running 
buffer. 
After the samples have been boiled they are spun down briefly. Before loading the samples on the 
gel there was loaded 10 µl of Pageruler Plus Prestained Protein Ladder (Fermentas) on the gel. 
Depending on how many wells the gel contained 15-20 µl of the samples were loaded into the other 
wells of the gel. The order of the samples loaded on the gel was noted. The gel was run at 200V for 
approximately 30 minutes. After the run the gel was removed from the cassette and washed three 
times with deionized water. After washing the gel was stained with Coomassie Blue (Biorad) for 
one hour. After staining the gel was destained with deionized water so marker and protein bands 
could be seen. 
 
SDS-PAGE analysis was also used for the monitoring of the fimbriae structure and purity of the 
fimbria purification. However the method was a bit different that the one described previous.  
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The gel solution to make the gels for the SDS-PAGE was made (4 gels):  
 
32 ml of 15 % gel solution 
200 µl APS 10 % (ammonium Persulfate) 
10 µl TEMED (tetramethylethylenediamine) 
 
The solution was poured into four gel cassettes and the well frames were placed in the cassettes. 
The gels were left for polymerization at room temperature.  
 
The samples were prepared by addition of loading buffer. The samples were boiled for 5 minutes at 
100oC. The Mini-Cell chamber was assembled as described previously. Before sample loading 10 
µl Protein ladder was added in a well. Depending on the well size 20-30 µl sample was added into 
the wells. The sample order was noted. The gel was run at 125V for approximately 90 minutes. The 
gel was removed from the cassette after the run and washed three times with deionized water. Then 
the gel was stained with Imperial staining for approximately 1 hour before destaining with 
deionized water.    
 
Immobilized Metal ion Affinity Chromatography (IMAC) protein purification 
 
In the pET28a clone the MrkD protein was forming inclusion bodies. For this reason the 
purification of MrkD was done from the inclusion bodies under denaturing conditions by using 8 M 
urea. The purification was done by Immobilized Metal ion Affinity Chromatography (IMAC) with a 
1 mL His-Trap FF crude column from GE Healthcare Life Sciences, which binds Histidine-tagged 
proteins. The nickel ions (Ni2+) in the column bind to the Histidine-tagged proteins with higher 
affinity than proteins with no histidine-tag. For this reason, proteins without a histidine-tag are 
washed out under the wash step and the proteins containing the histidine-tag will remain bound to 
the nickel ions in the column. After the wash Histidine-tagged proteins can be eluted by using a 
high concentration of imidazole which results in relative pure protein [24, 25]. This method is very 
good for purification under denaturing conditions because it only depends on the primary structure 
of the protein.   
 
Four liters of inoculated LB media containing kanamycin was induced with 1 mM IPTG for three 
hours. Afterwards the cell suspension was centrifuged for 15 minutes at 7000 RPM. The 
supernatant was discarded and the pellet saved. One liter of cell pellet was resuspended in 10 mL of 
Sonication buffer (Appendix 1). The resuspended pellet was sonicated 5 x 3 minutes (2 sec. puls 
and 1 sec. pause) while kept on ice. After sonication the suspension was centrifuged for 60 minutes 
at 15,000 RPM and 4oC. The supernatant was discarded and the pellet resuspended in 10 mL 
Denaturering buffer pr. 1 liter pellet (Appendix 1). Then the pellet was resuspended in the buffer 
and homogenized by using an osterizer for 1 minute. The cell suspension was incubated overnight 
at room temperature and constant rotation. After overnight incubation the cell suspension was 
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centrifuged for 60 minutes at 12,000 RPM and 4oC. The supernatant was put into a new tube and 
the pellet discarded. Meanwhile the 1 mL His-trap FF crude column (GE Healthcare) was prepared 
by washing it with 20 mL of filtered miliQ water at a flow rate 1 mL/min. Then the column was 
washed with 15 mL of Denaturing buffer still at the flow rate 1 mL/min. Then the sample was 
loaded onto the column at a flow rate 0.5 mL/min. The flow-through was collected. After the 
sample had been loaded onto the column, the column was wash with 20 mL of Wash buffer at the 
flow rate 1 mL/min (Appendix 1). Once again the column flow-through was collected. Then the 
His-tagged protein had to be eluted. The elution was done with 10 mL Elution buffer and ten eluates 
of 1 mL were collected at a flow rate of 0.5 mL/min (Appendix 1). After elution the eluates were 
run on a SDS-PAGE and stored at 4oC until further use. 
 
Because the protein purification was done under denaturing conditions the protein has to be 
refolded after the purification and the urea had to be removed. Refolding was done by dialysis. The 
principle in dialysis is that unwanted molecules are removed by diffusion through a semipermeable 
membrane. The dialysis was done by decreasing the concentration of urea in the dialysis buffers. 
The eluate from the IMAC purification was placed into a dialysis bag which was put into two liters 
of Dialysis buffer 1 at 4oC for three hours (Appendix 1). After the three hours the dialysis bag was 
put into two liters of fresh Dialysis buffer 1 and left overnight at 4oC. The following day the dialysis 
bag was transferred to two liters of Dialysis buffer 2 (Appendix 1). After three hours in Dialysis 
buffer 2 at 4oC the dialysis bag was transferred into two liters of fresh Dialysis buffer 2 and left 
overnight at 4oC. The next day the content in the dialysis bag was transferred into an Eppendorf 
tube and centrifuged for 30 minutes at 12,000 RPM at 4oC. The supernatant was put into a new tube 
on run on a SDS-PAGE.    
 
Gel filtration 
 
Gel filtration was used to purify MrkD based on size. Gel filtration was performed on a FPLC 
(ÄktaTM) with a Gel Filtration Superdex 75 (GE HealthcareTM) column buffered with Tris buffer (50 
mM Tris, 150 mM NaCl, pH 7-7.5). The column was equilibrated with 10 ml of Tris buffer. 
Afterwards 1 mL sample was injected. The elution of the sample was done with 40 ml EQ buffer at 
a flow rate of 1 ml/min flow (Appendix 1). The absorbance was measured at 260 nm and 280 nm. 
Wash and reequilibration of the column was done afterwards.  
 
Casein digestion 
 
Digestion of casein was done in order to separate and test each fraction to see which fraction had an 
inhibitory effect on the agglutination of bacteria to yeast.  
 
A modified protocol from Turki et al., 2009 was used for digestion of casein. Trypsin (SigmaTM) 
was prepared in 1 mM HCL (1mg/ml) and casein was dissolved in 1 M NaOH (SigmaTM). To buffer 
exchange the casein solution, casein was dialyzed overnight in two liters of enzyme digestion buffer 
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(Appendix 1). Trypsin was added to the casein in a ratio of 1:250. Casein was digested overnight at 
37oC. The trypsin was inactivated by heating, 98°C for 10 minutes the following day. After 
inactivation of trypsin the digested casein was centrifuged. The supernatant was saved and used for 
Revers-Phase Chromatography and the pellet discarded.  
 
In silico digestion of casein  
 
Casein consists of four subtypes; an alfaS1, alfaS2, beta and kappa subtype. The amino acid 
sequence was obtained at NCBI pubmed. Online software ExPASyTM was used to predict the 
sequences of digested casein. Each one of the four casein subtypes was analyzed by itself. Trypsin 
was set as the digestion enzyme. The cut off was set at amino acids sequences over 500 Dalton. 
 
Reverse-phase chromatography 
 
Reverse-Phase Chromatography (RPC) was done to separate fractions from the digested casein 
based on hydrophobic abilities.  
 
A ResourceTM RPC C8 (GE HealthcareTM) column were used and connected to a FPLC (ÄktaTM). 
Two buffers were used to make the separation of digested casein; Equilibration buffer and Elution 
buffer (Appendix 1).  The separation of digested casein was started at a concentration of 2 % 
acetonitrile and was run to the concentration of acetonitrile reached 40 %. The flow rate was kept 
constant at 4 ml/minute and the absorbance was measured at 214 nm, 260 nm and 280 nm. Before 
the injection of 1 mL sample the column was equilibrated with 10 mL equilibration buffer. The 
eluted fractions stored at 4oC until they were tested in the agglutination assay. 
 
Agglutination assay 
 
The agglutination assay was used to screen for inhibitory properties of the digested and fractionated 
casein on the agglutination between bacteria and yeast.  
 
Bacteria were grown in 4 mL LB-media with appropriate antibiotic overnight at 37oC and 200 
RPM. The following day the strains were centrifuged at 4,000 x g for 4 minutes. The supernatant 
was discarded and the pellet resuspended in 4 mL Phosphate Buffered Saline (PBS). The wash step 
was repeated twice. The pellet was finally resuspended in 3 mL PBS. The yeast (“Malteserkors 
gær”, dry yeast) was prepared in a 1% (w/v) solution in PBS with 10 % (w/v) D-mannose.  
To make the agglutination, 25 µl of bacteria suspension, was mixed with 25 µl 1% yeast and 25 µl 
of each fraction of the digested casein. The glass slide was rotated clockwise and counter-
clockwise. Agglutination was visualized as a clumping of bacteria and yeast, while the surrounding 
liquid was clear. No agglutination was visualized by no clumping and the liquid staying turbid 
while agglutination was seen as a clumping of the cells and the surrounding liquid becoming clear. 
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When screening the different casein fractions, only the strains C3091 and C3091 ∆fim ∆mrk were 
used.  
Both a positive and negative control was tested on each glass slide together with the casein 
fractions. As the positive control the strain C3091 was used and as the negative control the strain 
HB101 pmrkABCF was used.  
 
Binding assay 
 
Without antibody 
 
Binding assays were made in order to see which ligands MrkD was binding to and to test under 
which condition the binding would increase or decrease. The method was also used to test which 
ligands could inhibit the binding of MrkD.  
 
Overnight cultures of the bacteria strain were made in LB media with appropriate antibiotic and 
incubated at 37oC and 200 RPM. The following day a 96-well plate was incubated with coating for 
one hour at 37oC. After one hour incubation with the coating the 96-well plate was washed three 
times with PBS. Bacteria strain was added to the wells. The 96-well plate with bacteria was 
incubated for half an hour at 37oC. After incubation the 96-well plate was washed three times with 
PBS. After the wash the 96-well plate was dried for 5 minutes at 60oC. When the plate was dry each 
well were stained with 100 µl of 0.1 % crystal violet for 20 minutes. The 96-well plate was washed 
three times with water after staining. Then 100 µl of 50 % ethanol was added to each well and the 
plate was shaken at 1,000 RPM for 5 minutes before OD600 was measured in each well.  
 
With antibody 
 
Binding assay with antibody was made in order to control if the ELISA plate had been coated 
properly with the pili used for testing the binding of MrkD.  
 
A 96-well plate was incubated with coating for one hour at 37oC. After one hour incubation with the 
coating the 96-well plate was washed three times with PBS. Then 150 µl of PBS+BSA was added 
to each well and the plate was incubated for 10 minutes at 37oC. This was done in order to block all 
unspecific binding to the plate. After incubation the buffer was removed from the wells and 100 µl 
of the primary antibody solution was added to each well (Appendix 1). The plate was then 
incubated for 40 minutes at 37oC. The plate was washed six times with PBS after incubation with 
the primary antibody. After the wash 100 µl of the secondary antibody solution was added to each 
well (Appendix 1). Again the plate was incubated for 40 minutes at 37oC.  Once again the plate was 
washed six times with PBS after the incubation. After the wash 100 µl of TMB peroxidase reaction 
solution was added to each well (Appendix 1). The plate was shaken very carefully and OD650 was 
measured in each well.  
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With Horse-Radish-Peroxidase (HRP) 
 
Binding assay with HRP was made in order to control if the ELISA plate had been coated properly 
when testing the MrkD binding. The HRP catalyze the oxidation of the chromogenic substrate TMB 
peroxidase leading to colored product/detectable signal which can be read by a spectrophotometer.  
 
A 96-well plate was incubated with coating for one hour at 37oC. After one hour incubation with the 
coating the 96-well plate was washed three times with PBS. Then 150 µl of PBS+BSA was added 
to each well and the plate was incubated for 10 minutes at 37oC. This was done in order to block all 
unspecific binding to the plate. After incubation the PBS+BSA buffer was removed from the wells 
and 100 µl of the HRP solution was added to each well (Appendix 1). The plate was then incubated 
for 40 minutes at 37oC. After the incubation the plate was washed six times with PBS. The solution 
was removed from each well with vacuum the first two times of washing and the remaining washes 
were done by invertion of the plate. After the wash 100 µl of TMB peroxidase reaction solution 
(Thermofisher) was added to each well. The plate was shaken very carefully and OD650 was 
measured in each well.  
 
Pili purification 
 
The pili purification was done in order to obtain pure pili that could be used for the testing of MrkD 
binding. 
 
For the pili purification six liters of overnight culture in LB media with the appropriate antibiotic 
was made. The overnight culture was incubated at 37oC and 200 RPM. The following day the 
culture was spun down at 8,000 RPM. The pellet was transferred to new tube and resuspended in 
15-25 ml Pili buffer. Afterwards, the pellet was osterized at ice in one minute and one minute pause, 
this was repeated five times. After osterization the cell debris was centrifuged for 15 minutes at 
12,000 RPM. The supernatant was transferred to a new tube and the pellet was discarded. Then 2 M 
MgCl2 was added to the supernatant to get the final concentration 0.2 M (Appendix 1). When the 
MgCl2 had been added to the supernatant the sample was rotated at room temperature for at least 
one hour. After one hour rotation the sample was centrifuged at 12,000 RPM for 20 minutes at 4oC. 
The supernatant was discarded and the pellet resuspended in 1-3 ml Pili buffer. The resuspended 
sample was centrifuged for five minutes at 12.000 RPM. The supernatant was transferred to a clean 
tube. Once again MgCl2 was added to the sample to get the final concentration 0.2 M. The sample 
was rotated overnight at 4oC. The following day the sample was centrifuged for 20 minutes at 
12,000 RPM. The supernatant was discarded and the pellet was resuspended in 1-2 ml HBS-PE 
buffer (Appendix 1). The sample was rotated for 30 minutes at room temperature. After rotation the 
sample was centrifuged for five minutes at 9,000 RPM. The supernatant was transferred to a new 
tube. Next the pili concentration was measured by using the BCA method. 
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BCA measurement of protein concentration 
 
The BCA assay was used to measure the pili concentration in the samples with purified pili. 
 
PierceTM BCA protein assay kit was used for measurement of protein concentration. The sample 
was prepared by mixing 16 µl of super pure water with 2 µl of the purified pili and 2 µl of HCl 1M. 
The sample was boiled on a heating block for 5 minutes at 100oC. Meanwhile it was calculated how 
much BCA Working Reagent was needed to the assay (Appendix 1). There was added 200 µl of 
BCA Working Reagent to each well. Then 20 µl of sample and standards were added to the wells. 
The plate was shaken carefully and was then incubated for 30 minutes at 37oC. After the incubation 
OD562 was measured in each well.  
 
Transmission Electron Microscopy (TEM) 
 
The transmission electron microscopy was used to take pictures of type 1 fimbriae the native form 
and after treatment with SDS/boiling and glycerol/boiling. The samples were prepared in the 
laboratory but the microscopy was done by a specialist at University of Washington. 
 
The sample preparation was done by making 20 µl of pili solution in the concentration 0.5 mg/ml. 
The pili solution without any treatment was the control of the native conformation of the pili. To 
make the glycerol-treated sample, glycerol was added to the pili solution to get the final 
concentration of 50 % glycerol. The sample was incubated for 4 hours at 37oC. After incubation the 
sample was boiled on a heating block for 5 minutes at 100oC.   
 
The SDS-treated sample was made by adding SDS to the pili solution to the final concentration of 
2.5 % SDS. The sample was boiled on a heating block for 5 minutes at 100oC. 
 
After the sample preparation 4 µl of each sample was added on carbon grids for electron 
microscopy. The samples were incubated on the grids for 10 minutes at room temperature. After the 
incubation the remaining fluid was removed from the grids by dabbing on filter paper very 
carefully. The grids were then stained with Nano-W for one minute. After the staining the grids 
were washed two times with a drop of water. The remaining fluid was removed by dabbing on filter 
paper. The grids were left at room temperature to air-dry. When the grids were completely dry, they 
were put into a grid box and left in a desiccator until the microscopy was performed.  
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Statistic 
 
All binding assays were performed in either triplicate unless otherwise stated. The average value 
and standard deviation were calculated from the triplicates.   
 
The % of MrkD binding to the ligands was calculated by the equation: 
𝑦
𝑥
 × 100%  
 
Example:  
MrkD binding to ligand
MrkD binding to uncoated plastic
× 100 % 
 
 
 
The reduction in MrkD binding was calculated by: 100 % - % MrkD binding to ligand  
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 Results 
 
Protein expression 
 
The adhesin of type 3 fimbriae is MrkD. To test the adhesive properties of MrkD, the gene was 
cloned into a plasmid vector. The plasmid vector containing the gene for MrkD was transformed 
into a protein expression host. This was done in order to get as much protein expressed as possible 
which should be purified and tested.    
 
pET24d + mrkD 
 
The first plasmid vector tested was pET24d in which the mrkD gene had been cloned into. The 
plasmid containing mrkD was transformed into the BL21(de3) strain. The protein expression was 
initiated by the addition of IPTG. The IPTG induction was going on for 3 hours at 37oC. However 
after the 3 hours no difference between uninduced and induced samples was seen, when analyzed 
by SDS-PAGE (Figure 9).  
 
Figure 9: Results of SDS-PAGE analysis of the IPTG induction of the BL21(de3) cells containing the 
plasmid pET24d with the mrkD gene.  
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Different induction times were tested, but still no difference between the uinduced and induced 
samples was seen. Since no visible difference between the uninduced and induced samples was seen 
on a SDS-PAGE gel, I tried to run the IPTG induced sample on a gel filtration column on a FPLC. 
The collected fractions from the gel filtration were run on a SDS-PAGE analysis afterwards. 
However, the fractions from the gel filtration showed no clear protein band corresponding to the 
size of MrkD (Data not shown). 
 
To see if the protein expression could be increased in another way the IPTG induction was 
performed in three different media and at three different temperatures. In addition, the induction 
was performed for three different lengths of time. The three different media used for the experiment 
were LB media, 2x YT media and Terific broth media. The temperatures were set to 18oC, 28oC and 
37oC. The induction time was set to 1 hour, 3 hours and overnight. However when analyzed by 
SDS-PAGE after the induction, still no difference between the uninduced and induced samples were 
seen in any of the three media.  
 
The last attempt was to induce the BL21(de3) cells containing pET24d + mrkD in Magic media. 
The media was said to yield a 3-10 times higher protein expression. However, again no difference 
between uninduced and induced samples was seen when analyzed by SDS-PAGE. Therefore 
another plasmid containing mrkD was examined. 
 
pET28a + mrkD 
 
The plasmid pET28a was another plasmid in which the mrkD gene also had been cloned into. The 
plasmid had been transformed into BL21(de3) cells. Next the BL21(de3) containing the plasmid 
was induced with IPTG for 1 and 3 hours in LB media at 37oC. When analyzed with SDS-PAGE 
the induced samples showed high protein expression but the protein remained in the pellet as 
inclusion bodies (Figure 10). To see if the removal of the signal peptide of mrkD had an influence 
on the protein expression, the signal peptide was removed from the construct by PCR and ligation. 
However, even with the signal peptide removed there was still a high protein expression leading to 
formation of inclusion bodies (Data not shown).  
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Figure 10: Results of SDS-PAGE analysis of one and three hours IPTG induction of the BL21(de3) cells 
containing the plasmid pET28a with the mrkD gene. 
 
Inclusion bodies are aggregated proteins that are formed in the cytoplasm of the bacteria yield to 
high level of expressed recombinant protein [26]. The problem with inclusion bodies is that the 
proteins are denatured and have to be purified and refolded. This can be quite tricky since the 
procedure depends on the specific protein that has to be purified and refolded.  
    
pET26b + mrkD 
 
A construct containing a partial sequence of the mrkD gene had successfully been purified by others 
[27]. This sequence is believed to be the binding domain of MrkD. The protein had shown to be 
expressed in the periplasm of the bacteria from where it was purified. For this reason a construct 
containing this sequence was ordered from GenScript. First the plasmid was transformed into 
BL21(de3) cells. Then the BL21(de3) strain containing the plasmid was induced with IPTG. To see 
at which condition yield the best protein expression IPTG induction was tried for 1 and 3 hours and 
overnight at 37oC and with three different IPTG concentrations (0.1 mM, 0.5 mM and 1 mM). 
However when analyzed by SDS-PAGE no difference was seen between the uninduced and induced 
samples (Figure 11). 
Page 37 of 78 
 
    
Figure 11: Results from the SDS-PAGE analysis of three hours IPTG induction of BL21(de3) cells 
containing the plasmid pET26b with partial mrkD gene.   
 
Because no difference was seen between the uninduced and induced samples at 37oC, the IPTG 
induction was tried at 18oC and 28oC instead. This induction was carried out for 1 and 3 hours and 
the IPTG concentration was 0.1 mM. Afterwards the samples were analyzed by SDS-PAGE, 
however only a tiny difference was seen between the uninduced and induced samples at the 
induction at 28oC (Figure 12). 
 
Page 38 of 78 
 
 
Figure 12: Result of SDS-PAGE analysis of IPTG induction at 28oC of BL21(de3) cells containing the 
plasmid pET26b with partial mrkD gene.   
 
However the difference was so little that the periplasmic protein purification was not carried. This 
was due to that the protein amount was too little to yield enough protein for testing the adhesive 
properties. 
  
IMAC purification 
 
Since one plasmid did not express any protein and another only very little the protein purification 
was only performed for one of the three plasmids.  
 
The protein expression of mrkD with the plasmid pET28a was so high, that it formed inclusion 
bodies. For this reason the protein purification of mrkD had to be done from the inclusion bodies. 
To purify proteins from inclusion bodies the organic compound urea has to be use, because it 
solubilizes the inclusion bodies. The issue with urea is that it is a denaturing agent, so the expressed 
protein will be fully denatured by this treatment. However after the inclusion bodies have been 
solubilized the protein can be purified by using IMAC and dialysis can be used to refold the 
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proteins afterwards. After IPTG induction the cell pellet was destroyed by sonication. When the 
pellet had been sonicated, urea was added to the cell suspension to denature the inclusion bodies 
totally. The MrkD protein was purified by IMAC. The eluates collected from the IMAC were run 
on a SDS-PAGE analysis. The SDS-PAGE analysis showed that MrkD was purified by IMAC 
(Figure 13). MrkD was seen as a clear band of approximately 30 kDa on the gel from SDS-PAGE 
analysis.  
 
Figure 13: SDS-PAGE analysis of the flow-through and eluates collected from the IMAC purification of 
MrkD from the pET28a plasmid. 
 
Now that MrkD had been purified in a denatured form it had to be refolded to its native form by 
removal of the urea. The eluates containing MrkD was dialyzed over to days in two different 
dialysis buffers with decreasing concentration of urea. Unfortunately the protein precipitated in the 
dialysis buffer. To avoid the precipitation of the protein different dialysis buffers were tried out. 
Dialysis buffers containing different concentration of NaCl, different pH values and with the 
addition of glycerol was tried to get the protein to refold. However none of the dialysis buffers 
worked and the protein precipitated in all of them.      
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Adhesive properties of MrkD 
 
It had not been possible to overexpressed and purify  MrkD adhesin  so instead E. coli strain 
expressing type 3 fimbriae (STL-327) was used to explore the adhesive properties of MrkD. To 
make sure that the binding of bacteria is caused by MrkD adhesin, the E. coli strain that expressed 
the type 3 fimbriae without the MrkD adhesin (HB101 pmrkABCF) was used as a control. Different 
ELISA assays were performed to investigate the binding properties of MrkD.  
 
To screen a specificity of MrkD binding, the ELISA assays with different types of ligand coated on 
the microtiter plate surface have been performed. As shown in Figure 1, MrkD-expressing bacteria 
(STL-327) bound to all coated ligands, including the uncoated wells. In contrast, the HB101 
pmrkABCF strain that does not contain the mrkD gene and therefore does not express the adhesin 
did not bind to any of tested ligands or plastic surface (Figure 14).  These results indicated that 
binding of STL-327 to the ligands and uncoated plastic surface is mediated by MrkD adhesin.  
 
 
Figure 14: Binding of HB101 pmrkABCF and STL-327 to different ligand coated on the microtiter surface. 
Binding to casein, BSA, collagen VI, was tested in triplicates and binding to FimH lectin domain, tryptone 
and trypsin was tested in duplicates. Each of the ligands were coated in microtiter wells in the concentration 
0.2 mg/ml and the bacteria were used in the final concentration OD600=2.  
 
Next I tested potency of these ligands to inhibit the binding mediated by MrkD. For this purpose 
one of the ligand, BSA, has been coated on the microtiter surface and MrkD-expressing bacteria 
were added to the BSA-coated wells in the presence of different concentrations of soluble ligands. 
As shown in Figure 15, the inhibition of MrkD binding was observed only for very high 
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concentrations of casein and randomly selected pure peptide from Synpep (SIRTDKDETTEKYHY-
cys-COOH) but not for trypton.  
 
Figure 15: The inhibitory effect of different ligands on the binding of MrkD to BSA. The plate was coated 
with 0.2 mg/ml BSA and the bacteria were used in the final concentration OD600=2. 
 
To test whether the inhibitory effect of casein is specific for MrkD, I also examined its effect on 
binding activity of another fimbrial adhesin for which ligand specificity is known, FimH adhesin of 
E.coli type 1 fimbriae. FimH recognizes mannose-containing ligands and its binding can be 
specifically inhibited by mannose [19]. While binding of FimH to mannosylated glycoprotein, 
RNaseB, was strongly inhibited by mannose, mannose had no effect on MrkD binding (Figure 16A 
and B). At the same time, casein inhibited both adhesins equally well indicating that inhibitory 
effect of casein is rather unspecific and most probably results from high concentration of the ligand. 
For this reason it can be concluded that casein does not have a specific inhibitory effect on MrkD 
binding, because the same effect is seen for mannose-specific type 1 fimbriae.  Taking together, all 
tested here ligands are bound by the MrkD adhesin when coated on the plastic surface but they do 
not specifically block the MrkD binding when added in the soluble form. 
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Figure 16: A: Inhibitory effect of different ligands on the binding of MrkD to RNAseB. B: Iinhibitory effect of 
different ligands on the binding of type 1 fimbriae to RNAseB. The microtiter plate was coated with 0.2 
mg/ml RNAseB and the bacteria solutions were used in the final OD600=1. 
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Interestingly, screening of different ligands for MrkD binding revealed that the only protein that 
was not bound well by MrkD was E.coli type 1 fimbriae (Figure 17). This appeared to be interesting 
considering the ‘super sticky’ properties of MrkD.  
 
 
Figure 17: Binding of MrkD to different ligands. The ligands were tested in triplicates. The microtiter wells 
were coated in the concentration 0.2 mg/ml and the bacteria solutions were used in the finale OD600=2.  
 
MrkD binding to type 1 fimbriae from E. coli 
 
To further examine the effect of type 1 fimbriae on MrkD binding different variants of type 1 
fimbriae have been included to the study. These comprised the type 1 fimbriae expressed with 
different variants of FimH adhesin or different variants of major fimbrial subunit, FimA. The results 
from the binding assay are presented in Table 4.  The FimH variants were all made from adhesin 
variant K12_F by introduction of single mutations. K12_F was created from K12 wild type 
adhesin by replacement of a short peptide in lectin domain (from inter-domain region). All the 
FimH variants contain the same FimA subunit [28]. These results showed that different FimH 
mutants of type 1 fimbriae have different potency to block the MrkD binding to the plastic surface. 
While coating of the plate with the N135I_F variant blocked the MrkD binding with 81 % (as 
compared to uncoated plastic), another FimH variant G79R blocked the binding only with 28 %. 
However, there were no pattern between the different FimH variants of type 1 fimbria and their 
inhibitory potency against MrkD binding. In particular, the level of MrkD binding did not correlated 
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with the activity of the FimH adhesin. For example, low level of MrkD binding was seen to both 
high and low activity FimH variants.  
 
The binding of MrkD to the different Type 1 fimbriae FimA variants were also examine. The ratio 
of FimA subunits in fimbrial shaft is much higher than FimH adhesin. Type 1 fimbriae are 
composed of up to 1000 FimA subunits but contain only a single copy of FimH adhesin [6, 19]. 
Therefore it is more likely that the FimA subunit could affect the MrkD binding. The fimbriae with 
five different variants of FimA and three different single mutatants of FimA subunit were 
examined. Of note, all of them contained the same variant of FimH adhesin from E. coli K12. The 
results showed different potency of the FimA variants to block the binding of MrkD (Table 4). The 
FimA variant EcoR52single mutationI showed the highest blocking of MrkD (47 %) while the variant 
EcoR60 showed the lowest blocking (9 %) when compared to uncoated plastic.   
 
Type 1 fimbriae with different variants of the FimH adhesin (but the identical variant of the pilin 
FimAK12) mediated diverse MrkD-dependent adhesion. In contrast, type 1 fimbriae with the same 
FimH (FimHK12) but different variant of FimA showed rather similar level of binding that 
corresponded to FimHK12-FimAK12 fimbriae. To definitively discriminate whether variant/activity of 
FimH adhesin play any role in MrkD interactions with the fimbriae, the MrkD-dependent binding 
was tested to pure fimbrial tips of the type 1 fimbriae. The fimbrial tips, build by minor fimbrial 
protein FimG, FimF and FimH adhesin were expressed in the complex with FimC chaperon [19, 29, 
30]. The binding of MrkD to pure tips was examined for the FimH variant KB91 from E. coli F18 
(with very low affinity towards mannose) and for FocH variant which is the mutant of K12 FimH 
that carry modification in the pilin domain and binds mannose with high affinity. However both 
isolated tips had very limited potency to block MrkD binding (Table 4).   
 
 
Table 4: Shows the binding of MrkD (STL-327) to different pili types and adhesins calculated in %, the 
standard deviation in % and binding reduction in %.  
Ligand Variant 
name 
MrkD binding 
(%) 
Standard deviation 
(%) 
Binding reduction 
(%) 
Uncoated wells - 100 % 6 % 0 % 
BSA - 100 % 2 % 0 % 
Type 1 fimbria 
FimH variants 
K12_F* 59 % 7 % 
 
41 % 
 Q133N_F 39 % 18 % 61 % 
 N135I_F 19 % 11 % 81 % 
 D54E_F* 31 % 2 % 69 % 
 82A_F* 28 % 8 % 72 % 
 G79R* 72 % 4 % 28 % 
 F1A_F 42 % 5 % 58 % 
Type 1 fimbria 
FimA variants 
EcoR52 78 % 3 % 
 
22 % 
 EcoR36 63 % 12 % 37 % 
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 EcoR60single 
mutation 
89 % 3 % 11 % 
 K12single 
mutation 
81 % 5 % 19 % 
 536single 
mutation 
83 % 2 % 17 % 
 EcoR52single 
mutationII 
70 % 4 % 30 % 
 EcoR60 91 % 5 % 9 % 
 EcoR52single 
mutationI 
53 % 11 % 47 % 
Fimbrial tip KB91 77 % 12 % 23 % 
 FocH 85 % 8 % 15 % 
*: The % of binding is calculated against the binding of STL-327 to BSA.  
 
As previously mentioned the adhesin of type 1 fimbriae, recognize mannose-containing ligands. 
Therefore the binding of FimH can be inhibited by mannose. To exclude the possibility that MrkD 
binding to type 1 fimbriae-coated surfaces (presented in Table 4) was due to mannose-dependent 
interactions between FimH adhesin and the bacterial surface all the binding assays were also 
performed in the presence of α-D-mannose (data not shown). No difference in the bacterial 
adhesion was observed between the absence and presence of α-D-mannose, which indicated that the 
observed bacterial binding is MrkD-dependent. 
 
Structural change of type 1 fimbriae influence on MrkD binding 
 
Type 1 fimbriae represent the rigid helical polymer of FimA subunit, with up to 1000 FimA 
subunits per fimbrial shaft. Because MrkD showed the high level of binding to monomeric ligands 
(BSA, tryptone etc., as shown in figure 17) I examined whether the surface protective properties of 
type 1 fimbriae could be due to theirs polymeric rigid structure. It has been shown that treatment of 
the fimbriae with HCl under very high temperature results in their depolymerization to single 
subunits. Therefore three different FimH variants of type 1 fimbriae were treated with HCl and 
boiled and MrkD binding was tested to both native and depolymerized fimbriae in parallel. The 
results showed increased MrkD binding to all type 1 fimbriae variants when they had been 
depolymerized (Figure 18). In fact the binding of MrkD increased to the same level as this observed 
to for uncoated plastic. The same result was observed for the FimA variants of type 1 fimbria (Data 
not shown). 
 
 
 
Page 46 of 78 
 
 
Figure 18: Binding of MrkD to different FimH variants of type 1 fimbriae from E. coli in native 
conformation or depolymerized with with HCl/boiling. The microtiter wells were coated in the concentration 
0.2 mg/ml. The bacteria were used in the finale concentration OD600=1.    
 
To verify conformational state of the fimbriae both the untreated and HCl-treated fimbriae were 
analyzed by SDS-PAGE. Depolymerized fimbriae will be seen in the gel as protein band with size 
~17 kDa corresponding to size of the major subunit, FimA [31]. No band will be seen for intact 
fimbriae as the polymeric form due to big size will not migrate into the gel. As expected, ~20 kDa 
band was detected in SDS-PAGE only for HCl-treated fimbriae but not for the PBS-prepared 
fimbrial samples or samples treated with SDS only (Figure 19A).  
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Figure 19: A. SDS-PAGE gel of native and depolymerized type 1 fimbria FimH variant N135I_F. The gel 
was stained with Imperial staining. B. Binding of MrkD to type 1 fimbria variant N135I_F treated with SDS. 
The microtiter wells were coated in the concentration 0.2 mg/ml. The bacteria were used in the finale 
concentration OD600=1     
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This latter observation was surprising as the accompanying SDS-PAGE experiment the ELISA 
assay (Figure 19B) showed that MrkD binding increases also in case of SDS-treatment only (in the 
absence  of HCl), yet without fimbriae depolymerization (Figure 19A).  
SDS is an anionic surfactant known to unfold tertiary and secondary structures of proteins by 
disrupting non-covalent bonds responsible for maintaining a protein conformation [26, 32, 33]. 
Binding of SDS to the protein causes disrupting the non-covalent bonds and at the same increases 
the negative charge of the protein.  
 
To address the question about the effect of SDS on increased MrkD binding to type 1 fimbriae 
(without fimbriae depolymerization), I examined whether SDS-treated fimbriae coat the surface to 
the same extent as the untreated one. This control was important as, MrkD is very potent to bind to 
uncoated plastic (Figure 16). For this purpose the SDS-treated fimbriae were immobilized on a 
plastic surface and probe with soluble HRP. The latter can be easily detected using its oxidative 
properties and specific chromogenic substrate (see material and methods). Also, HRP was 
previously found in Sokurenko’s lab to have high capability to stick to plastic and hence be a good 
indicator of empty (uncoated) surface (unpublished data). 
 
The result from this control experiment with two different fimbriae variants is shown in Figure 20A 
and B. I detected that coating of the plate surface with type 1 fimbriae was concentration–dependent 
and the best covering of the plastic was seen with the high concentrations (0.4 mg/ml and 0.2 
mg/ml) of the fimbrial preparations. Still, even the highest concentration of the fimbriae (0.4 
mg/ml) was not as efficient in coating as BSA. Interestingly, wells with SDS-treated fimbriae 
showed diverse results for HRP binding. For N135I_F variant I observed increased HRP binding 
that correlated with increased MrkD binding indicating that the increased binding of the latter most 
probably results from not efficient plastic coating by SDS-treated fimbriae. However, SDS/boiling 
treatment of type 1 fimbria with K12 FimH showed adequate cover of the plastic (with low HRP 
binding) but still there was increase in MrkD binding (Figure 20B and 21). Therefore these results 
did not arbitrary determined the effect of SDS on MrkD binding.  To examine further the effect of 
SDS on type 1 fimbria, transmission electron microscopy (TEM) was performed on the SDS-treated 
fimbriae. The microscopy showed that SDS presence did not change the polymeric coiled shape of 
the fimbriae (Figure 22B). Therefore SDS must have another effect on the fimbriae than the 
uncoiling them. However this problem needs further investigation. 
 
    
 
 
 
 
 
 
 
Page 49 of 78 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0
.4
 m
g/
m
l
0
.2
 m
g/
m
l
0
.1
 m
g/
m
l
0
.0
5
 m
g/
m
l
0
.0
2
5
 m
g/
m
l
0
.4
 m
g/
m
l
0
.2
 m
g/
m
l
0
.1
 m
g/
m
l
0
.0
5
 m
g/
m
l
0
.0
2
5
 m
g/
m
l
N
at
iv
e
SD
S
SD
S 
b
o
ile
d
H
C
l b
o
ile
d
U
n
co
at
e
d
BSA K12 fimriae K12 fimbriae Plastic
O
D
6
5
0
HRP control of plate-coated with type 1 fimbriae 
variant K12
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0
.4
 m
g/
m
l
0
.2
 m
g/
m
l
0
.1
 m
g/
m
l
0
.0
5
 m
g/
m
l
0
.0
2
5
 m
g/
m
l
0
.4
 m
g/
m
l
0
.2
 m
g/
m
l
0
.1
 m
g/
m
l
0
.0
5
 m
g/
m
l
0
.0
2
5
 m
g/
m
l
N
at
iv
e
SD
S
SD
S 
b
o
ile
d
H
C
l b
o
ile
d
U
n
co
at
e
d
BSA N135I_F fimbriae N135I_F fimbriae Plastic
O
D
6
5
0
HRP control of plate-coated type 1 fimbriae variant 
N135I_F
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: A. HRP reaction when coating with BSA and type 1 fimbria variant N135I_F in different 
concentrations and after treatment with SDS, SDS/boiling and HCl/boiling. B. HRP reaction to coating with 
BSA and type 1 fimbria variant K12_F after treatment with SDS, SDS/boiling and HCl/boiling. The SDS-
treated fimbriae were all used in the concentration 0.2 mg/ml. All the samples were tested in triplicates. 
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Figure 21: Binding of MrkD to type 1 fimbria variant K12_F treated with SDS. The microtiter wells were 
coated in the concentration 0.2 mg/ml. The bacteria were used in the finale concentration OD600=1 
 
 
Figure 22: Transmission electron microscopy of (A) native type 1 fimbria (N135I_F) and (B) SDS-treated 
type 1 fimbria (N135I_F). Both samples were made in the concentration 0.5 mg/ml and stained with NanoW.     
 
It is important to mention that HCl/boiling-treatment of both fimbrial variants caused their 
depolymerization and provided complete coating of the plastic surface that blocked HRP binding 
but not MrkD. Thus the intact polymeric structure of type 1 fimbriae appears to be an important 
factor for their “blocking properties” of MrkD binding to the surface. It indicates that the polymeric 
structure of type 1 fimbriae protects them from adhesion.  
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Thus yet another unfolding treatment for the fimbriae and the MrkD binding was examined. 
Glycerol has been shown to have an unraveling effect on type 1 fimbria without destroying the 
polymeric structure [34] (Figure 24B). However, the results with glycerol-treated type 1 fimbria 
showed that they still had a potency to block MrkD binding (Figure 23). To ensure that the fimbria 
had been unraveled by the glycerol-treatment transmission electron microscopy of the fimbria was 
performed. However the transmission electron microscopy of glycerol-treated type 1 fimbriae 
examined in this thesis did not seem to be unraveled by the glycerol (Figure 24C). Therefore it was 
not clarified if the structure of type 1 fimbria causes the blocking of MrkD binding. 
 
 
Figure 23: Binding of MrkD to uncoated wells and to type 1 fimbria N135I_F in its native conformation, 
depolymerized with HCl/boiling and treated with 50 % glycerol. The samples were made in triplicates. The 
microtiter plate was coated in the concentration 0.2 mg/ml. The bacteria were used in the finale 
concentration OD600=1.  
 
0
0.1
0.2
0.3
0.4
0.5
0.6
boiled Boiled
with HCl
Not
boiled
With HCl,
no boiling
Boiled Boiled
with HCl
Native Depolymerized
No
coating
Type 1 fimbria (N135I-F) Type 1 fimbria (N135I-F) treated with
50% glycerol
O
D
6
0
0
Binding of MrkD to glycerol treated type 1 
fimbriae variant N135I_F
HB101 pmrkABCF
STL-327
Page 52 of 78 
 
 
Figure 24: Scanning electron microscopy pictures of (A) native and (B) glycerol-treated type 1 fimbriae [34] 
and (C) transmission electron microscopy of glycerol-treated FimH variant of type 1 fimbria (N135I_F).  
 
MrkD binding to CFA/I and CS17 pili 
 
Next it was examine whether the ‘blocking properties’ was unique for type 1 fimbriae only or if 
other fimbrial types also had the ability to block MrkD binding to uncoated plastic surfaces. The 
two other types of fimbriae included in the study were CFA/I pili (Colonization factor antigen pili) 
and CS17 pili (Coli Surface antigen 17) which both mediates adhesion to intestinal epithelia in the 
initiation of an infection [35]. The result showed that CFA/I pili did not have blocking potency of 
MrkD binding (Table 5). The binding was only reduced with 9 % for the CFA/I pili R182A while 
no reduction was seen for the variant R67A. Meanwhile protection of MrkD-dependent binding was 
seen for CS17 pili (Table 5). The reduction in MrkD binding was 87 % for one variant of CS17 pili 
(LSN-3) while the lowest reduction in binding was 54 % for the variant WS-E.   
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Table 5: Shows the MrkD binding to CFA/I and CS17 pili in %, standard deviation and the reduction of 
binding in %.   
Ligand Variant 
name 
Binding of 
MrkD (%) 
Standard deviation 
(%) 
Binding reduction 
(%) 
CFA pili S138A 96 % 2 % 4 % 
 R182A 91 % 3 % 9 % 
 R67A 100 % 8 % 0 % 
CS17 pili LSN-2 22 % 3 % 78 % 
 LSN-3 13 % 3 % 87 % 
 WS-E 46 % 5 % 54 % 
 
CFA/I and CS17 pili also represent a rigid helical structure composed of polymers of their 
respective major subunits like type 1 fimbria. Therefore the protective properties of the CS17 pili 
surface were examined. The depolymerization of the CS17 pili with HCl/boiling resulted in an 
increase in MrkD binding (Figure 25) which was also seen for type 1 fimbria. As expected 
depolymerization of CFA/I pili had no influence on MrkD binding. To verify that the pili were 
native and depolymerized they were run on a SDS-PAGE gel. However protein bands of the major 
fimbrial subunit was seen for both native and depolymerized pili (Figure 26). This indicates that 
SDS is able to depolymerize CFA/I and CS17 pili. However SDS was not able to depolymerize type 
1 fimbria.  
 
 
Figure 25: Binding of MrkD to uncoated plastic, type 1 fimbria (N135I_F), CS17 pili and CFA/I pili in both 
native conformation and depolymerized form. Each sample was tested in triplicates. The microtiter wells 
were coated in the concentration 0.2 mg/ml. The bacteria were used in the finale concentration OD600=1.  
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Figure 26: SDS-PAGE analysis of different CFA/I and CS17 pili variants in native and depolymerized form. 
The type 1 fimbria variant N135I_F was also tested. The pili were loaded onto the gel in the concentration 
0.2 mg/ml. The gel was stained with Imperial staining. 
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 Discussion  
 
Protein expression 
 
Three different plasmids each containing different versions of the mrkD gene from K. pneumoniae 
was transformed into BL21(de3) cells and induced with IPTG. However the constructs pET24 + 
mrkD and pET26b + mrkD did not express the protein and the construct pET28a + mrkD expressed 
the protein in inclusion bodies.  
Donor strand complementation 
 
The pET24d plasmid contained the mrkD gene and a complimented donor strand of the mrkA gene. 
Donor strand complementation is when the chaperon interacts with pilus subunits, which facilitates 
the folding of the subunit on a template of the chaperon. The pilus subunits are incomplete 
immunoglobulin (Ig) folds which results in grooves in the subunits that exposes the hydrophobic 
core. The chaperone can complete the Ig fold of the subunit by insertion of G1β strand into the 
hydrophobic core which is now protected (Figure 27) [30, 36].  
 
 
Figure 27: Donor strand complementation. 1. The pilus subunit is folded like an incomplete Ig fold leaving 
the hydrophobic core of the protein exposed. 2. The G1β strand of the chaperon is inserted into the 
“acceptor cleft” and completes the hydrophobic core of the pilus subunit. Modified [36].   
 
Normally it is a sequence of the chaperone that is used for donor strand complementation. In this 
case the donor strand complementation was tried with mrkA which is the major subunit of type 3 
fimbria. The adhesin MrkD is incorporated on the top of the fimbrial sharft which is composed of 
several subunits of MrkA. For this reason it was hypothesized that the sequence from mrkA would 
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fit into the exposed groove of MrkD. However no protein expression was seen for the pET24d 
plasmid containing mrkD and donor strand of mrkA. For type 1 fimbria it had been shown that it 
requires donor strand exchange of the G1β strand of chaperon to incorporate the next fimbrial 
subunit to FimH, which is the adhesin of type 1 fimbria. Donor strand exchange is when the N-
terminal extension of one subunit displaces the G1β strand of the chaperone in the new incoming 
subunit (Figure 28).  
 
Figure 28: Interaction of one pilus subunit to another. The N-terminal donor strand extension of one subunit 
is inserted into the acceptor cleft of the other subunit. Modified [36]. 
 
Not much is known about the structure of type 3 fimbria, but it has been suggested that it has the 
same structure as type 1 fimbria. The major structural proteins of type 1 fimbriae in E. coli 
demonstrates approximately 60 % homology to type 3 fimbriae e.g. mrkC shows approximately 50 
% similarities in the amino acids sequence of fimD (from E. coli type 1 fimbria) which have the 
same function [2, 37]. Therefore the pilus assembly of type 3 fimbria could be similar to the 
assembly of type 1 fimbria. If the principle is the same for type 3 fimbria it might be a reason why 
the construct did not express any protein. It should have been the donor strand complementation 
with the chaperon MrkB instead of major subunit MrkA. Others have also found in type 1 fimbria, 
that the adhesin FimH needs the donor strand complementation of the chaperone (FimC) in order to 
fold properly and be stable in the periplasm [38]. This shows that the pilus subunit do not contain 
all information necessary for folding and this information is then supplied through donor strand 
complementation [30]. Without the donor strand complementation of mrkB the adhesin MrkD could 
not be transferred to the periplasm or be folded properly. Usually improper folded proteins are 
degraded in the cell and this could be a reason why no protein expression is seen.     
 
Another issue when making constructs with donor strand complementation is that the sequence of 
the donor strand should be made in the reverse direction due to the protein folding. Unfortunately 
this was not considered when this construct was made and for this reason the sequence of the donor 
strand was in the forward direction. If the donor strand of mrkA had been the right orientation then 
the protein might have been folded properly which had stabilized protein and thereby avoiding 
degradation of the protein. 
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Polyhistidine tag 
 
All of the three construct used were tagged with a polyhistidine-tag composed of six histidine. In all 
constructs the His-tag was placed in the N-terminal of the mrkD gene. The N-terminal of the 
sequence is essential for the direction of the protein to the periplasm because it contains the signal 
peptide which directs the protein to the right place in the bacteria. The N-terminal is also crucial for 
the proper folding and function of the protein. Because the His-tag was placed in the N-terminal it 
could influence the transfer of the protein to the periplasm. For this reason the protein might not be 
directed to the periplasm for proper folding which lead to the degradation of the protein. This could 
be an explanation why no protein expression seen for the constructs pET24d and pET26b. This can 
also be an explanation of the formation of inclusion bodies in the construct pET28a. If the 
expressed proteins can not be transferred to the periplasm they can accumulated in the cytoplasm as 
inclusion bodies.  
The N-terminal of the protein also ensures that the protein is folded correctly. Therefore the His-tag 
in the N-terminal could interfere with the folding of the protein which leads to the destruction of the 
protein due to improper folding. This is also an explanation why no protein could be seen after 
IPTG induction for two of the constructs pET24d and pET26b.   
 
Meanwhile it has been shown that the greatest diversity in the amino acid sequence is seen in the N-
terminal of MrkD between the different variants of the adhesin. The N-terminal is thought to be 
region in which molecules are recognized and where the specificity of the recognition is. On the 
other side the most conserved amino acid sequence is seen in the C-terminal of MrkD. It has been 
suggested that the C-terminal facilitates the interaction of MrkD with the other fimbrial proteins and 
contains four motifs essential for folding and assembly of the fimbria [39]. A His-tag in the C-
terminal of MrkD might have had a different outcome than what was seen with the N-terminal His-
tag [24]. Although others have been able to express and purify the plasmid variant of MrkD with a 
N-terminal polyhistidine tag [40]. However, the plasmid-born and chromosomal variant of mrkD 
varies greatly in homology from 60-96 % [8]. For this reason a N-terminal His-tag may not interfere 
with the folding and transfer of the plasmid-born variant of mrkD while it could have an influence 
for the chromosomal variant of the gene. 
  
An advantage of the His-tag is due to its relatively small size which means that it rarely interferes 
with the protein activity. In principle the His-tag can be located in both the N- and C-terminal of the 
protein of interest and the choice depends on the protein of interest [24]. However in E. coli the 
expressed proteins is secreted by the N-terminal signal sequence, for this reason the His-tag must be 
placed in the C-terminal of the protein to prevent interfering with the signal sequence. The C-
terminal location of the His-tag should have no influence on the secretion of the protein [41]. For 
this reason the N-terminal His-tag could have an influence on secretion of the protein to the 
periplasm after all.  
 
Disadvantage of tags in general is; change of protein conformation, lower yield of protein, 
inhibition of enzymatic activity, alteration of biological activity, undesirable flexibility in structural 
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studies and toxicity. This applies especially for large tags. Therefore it is very desirable to remove 
the larger tags after purification of the protein. However the His-tag is considered to be a very small 
tag which normally is not removed [42]. Since no protein expression was seen for pET24d and 
pET26b removal of the His-tag was not considered. However the pET28a construct did express 
protein but the removal of the His-tag was not attempted due to the small size of the tag. Therefore 
it can not be excluded that removal of the His-tag could have influenced refolding of the protein.    
 
Besides His-tag other protein tags are also available e.g. GST-tag. To decide which tag should be 
used some considerations must be made like what the application of the purified protein is and 
which expression system is used. None of the tags is better than the other because it highly depends 
on the specific protein of interest [24]. Others have successfully been able to purify GST-tagged 
MrkD adhesin [43]. The GST-tag is a relatively large tag and is composed of glutathione S-
transferase (GST). Some of the major advantages of this tag are that it protects the protein from 
intracellular cleavage and stabilizes the protein. Before the protein can be used after purification it 
is recommended to remove the GST-tag from the protein. This is done by specific cleavage of the 
tag with e.g. thrombin or factor Xa [24]. It has also been shown that the GST-tag makes proteins 
more soluble [24, 42]. Therefore a GST-tag might have helped stabilizing the MrkD protein, which 
might have prevented the formation of inclusion bodies with the pET28a construct. However the 
GST-tag was not used for any of the three constructs. Thus, it would be interesting to see if a GST-
tagged fusion protein of MrkD would be able to be expressed as a soluble protein.    
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Protein purification 
 
The construct pET28a + mrkD formed inclusion bodies when induced with IPTG. Therefore the 
protein was purified from the inclusion bodies under denaturing conditions. The purification of the 
His-tagged MrkD with IMAC was possible. However it was not possible to refold the protein by 
dialysis. 
 
Inclusion bodies 
 
Inclusion bodies are aggregation of partially folded proteins which is accumulated in the cytoplasm 
[26]. Normally the solubilizing of the aggregate proteins requires strong denaturing conditions 
which indicate that the polypeptide chains of the protein are folded incorrectly [41]. Some of the 
factors that lead to the formation of inclusion bodies are: the lack of access to a chaperone, lack of 
enzymes that catalyze the folding and very high protein concentration with limited solubility of 
folding intermediates [26]. As described previously the N-terminal of a protein usually contains a 
signal sequence which is responsible for proper folding of the protein and transportation to the 
periplasmic space. Therefore the N-terminal His-tag in the pET28a construct might have interfered 
with the transfer and folding of the expressed protein leading to the formation of inclusion bodies in 
the cytoplasm. Another explanation could be the lack of access to a chaperon. In addition, the 
construct was not made with donor strand complementation of the chaperon, which could have 
stabilized the protein folding. However it is possible that the formation of inclusion bodies was due 
to the high expression level of the protein. A study of plasmid-born variant of mrkD also formed 
inclusion bodies from which the protein was purified [40]. This construct had a N-terminal His-tag 
like the construct pET28a used in this thesis. Therefore it is a possible that the N-terminal His-tag 
interferes with the transfer and folding of the protein leading to formation of inclusion bodies. 
 
Normally it is more desirable to work with and purify soluble protein than with inclusion bodies. 
The reason for this is that it is easier and time saving compared to purification of inclusion bodies. 
At the same time protein yield from inclusion bodies is only 20-25 % which means that more 
protein has to purify from the inclusion bodies to get the same amount of protein (Palmer and 
Wingfield 2004). Some changes of the protocol can be done in order to generate soluble protein 
instead of inclusion bodies e.g. change of the growth temperature or change of the extracellular 
environment [41]. However since time was a limited different incubation temperatures or media 
was not tried for the construct pET28a. It is possible that other incubation temperatures or different 
media could have contributed to soluble protein.   
  
Despite the formation of inclusion bodies it was possible to purify the MrkD protein by IMAC.  
 
 
  
Page 60 of 78 
 
Protein precipitation  
 
The formation of inclusion bodies is not very convenient since it usually is the native protein that is 
examined. However inclusion bodies can be refolded to their native conformation. This can be done 
by using refolding buffers [44]. However, refolding of the adhesin MrkD from the construct 
pET28a was not possible. 
 
Denaturants such as urea is usually used in high concentrations to solubilize the inclusion bodies. 
However when the inclusion bodies have been solubilized the denaturant has to be removed in order 
for the protein to refold. To get a successfully refolding of the protein the refolding conditions has 
to be optimal. It is a very critical step and is highly depended on the specific protein.  
A refolding buffer can contain both folding additives and folding enhancers to provide the optimal 
conditions for refolding. The folding additives are added in order to promote the refolding e.g. low 
concentration of denaturants sustains the protein intermediates in a soluble state[45]. In this 
experiment urea present in the concentration 1M in the first dialysis buffer, while the second 
dialysis buffer did not contain urea. Folding enhancers facilitate protein interactions and thereby 
stabilize the protein. Salt is one example of a folding enhancer because it stabilizes the protein 
through non-specific electrostatic interactions [56]. In this experiment both concentration of 150 
mM, 350 mM and 500 mM NaCl in the buffers were tried, however the MrkD protein precipitated 
despite the concentrations. Therefore the increasing salt concentration did not influence the folding 
of the protein in this experiment.  
Glycerol is also known to stabilize protein conformation. Glycerol enhances the hydrophobic 
interactions which lead to increased solvent ordering around the protein [56]. However the addition 
of 1 % glycerol to the buffer did not change the outcome and the MrkD protein still precipitated. 
However increasing concentrations of glycerol have shown to stabilize the protein and normally 5-
30 % glycerol is used to refolding [46]. However it had also been shown that too high concentration 
of glycerol decreases the refolding abilities of the proteins [56]. Therefore it can not be ruled out 
that a higher concentration of glycerol could have influenced the refolding of the MrkD protein.  
 
Most of the protein refolding is done in the pH range 5-9, although most proteins show the best 
refolding at pH 8-8.5. A general rule is that it is a good idea to use a buffer with a pH value at least 
one pH unit away from the isoelectric point (pI) of the refolded protein. If the protein has zero 
charge in the buffer it is more prone to precipitation [46]. The pI value of MrkD (accession no. 
AGZ83319.1) was 9.18 when predicted with ExPAsy. Different pH values from 3-11 were tried in 
the dialysis buffers, however the protein still precipitated in all of the buffers. 
 
The EDTA binds the metal ions in the solution [47]. When the protein has been purified on a nickel 
column, which the His Trap FF crude column is, some of the nickel ions might detach from the 
column and be in the solution with the purified protein. For this reason the addition of EDTA to the 
dialysis buffer will remove the metal ions from the solution. However neither the addition nor 
removal of EDTA had an influence on the refolding.  
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Other have successfully refolded MrkD protein from inclusion bodies by dialysis in PBS with 
decreasing concentrations of urea [40]. However the construct used in their experiment was tagged 
with a GST-tag while the construct (pET28a) used in this experiment had a His-tag. As previously 
described the protein tag can have stabilizing effect. Therefore it might be possible to refold MrkD 
protein with a GST-tag, while the His-tagged protein could not refold.   
 
Adhesive properties of MrkD 
 
The original idea was to test the binding of purify MrkD protein to different ligands in order to 
identify the receptor of MrkD. However the refolding of the purified MrkD protein was not 
possible. For this reason the MrkD binding was tested in another way by using an E. coli strain that 
expressed type 3 fimbria and thereby the MrkD adhesin. 
 
The E. coli strain STL-327 used for testing binding properties of MrkD contained a plasmid with 
the chromosomal mrk genes mrkABCF and an additional plasmid containing the mrkD gen. To 
ensure that the binding was caused by the MrkD adhesin  a negative control was tested in parallel. 
The strain used as the negative control was the E. coli strain HB101. This strain contains a plasmid 
encoding all the mrk genes (mrkABCF) with exception of mrkD. This means that the strain produces 
type 3 fimbriae but the fimbriae do not have any adhesins at the ends. One problem that have been 
demonstrated for type 1 fimbria is that without the adhesin the fimbrial assembly can not be 
initiated [30]. If this is the case for type 3 fimbria as well the fimbriae will not be expressed in the 
HB101 strain. However others have demonstrated that a MrkD-negative strain still produces type 3 
fimbrial-like appendages. The fimbria were not able to agglutinate mannose-treated human 
erythrocytes which indicates the absences of MrkD adhesin [2]. This shows that type 3 fimbriae still 
have an ability to assemble without the adhesin. It also shows that MrkD is the reason for 
agglutination of the mannose-treated erythrocytes and not the major fimbrial subunit MrkA [2, 48]. 
 
Another attempt to ensure that the binding was due only to MrkD was the addition of α-D-mannose 
to the assays. Normally E. coli strains express type 1 fimbria which binds to mannosylated receptors 
[49]. The addition of α-mannose in the assay will occupy the adhesin on type 1 fimbria because 
they will bind the α-D-mannose. Therefore the binding should be due only to MrkD on type 3 
fimbria. However the E. coli strains used here did not express type 1 fimbria. Therefore the addition 
of α-mannose was done as a safety precaution to make sure that the binding was due to MrkD 
binding only. Another thing to consider when using a recombinant E. coli strain is that there can be 
an quantitative difference in the expression of type 3 fimbria compared to the natural occurring type 
3 fimbria in K. pneumoniae [2]. 
 
The result from the binding assay showed that the MrkD-expressing strain STL-327 did bind to the 
tested ligands while the strain HB101 without MrkD did not bind. At the same time there was no 
significant difference in the binding of STL-327 when α-D-mannose was added to the assays. For 
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this reason it was concluded that the binding to the ligands was due to the binding of MrkD adhesin 
on type 3 fimbria.   
 
It had previously been found that type 3 fimbria binds to both glass and polypropylene surfaces [7]. 
It was suggested that high adherence and biofilm formation were due to MrkA (the major subunit of 
type 3 fimbria) because of its hydrophobicity which could overpower the electrostatic forces. 
However results from these binding assays showed no binding of HB101 strain to uncoated plastic. 
The HB101 strain contains a plasmid encoding mrkA and it has been shown that type 3 fimbriae can 
be assembled without the presences of MrkD adhesin [2]. Meanwhile the binding of the MrkD-
expressing strain (STL-327) was very high to uncoated plastic. This strain expresses all of the mrk 
genes which include both MrkA and MrkD. For the reason it was concluded that binding is due to 
the binding of MrkD only. However others have found that MrkA facilitates biofilm formation on 
plastic surfaces [20]. Therefore it can not be ruled out that MrkA can have an influence in the 
biofilm formation. However, here only the binding and not biofilm formation was tested.  
Though, in a clinically perspective catheters and other indwelling devices will over time be covered 
with extracellular matrix proteins to which MrkD binds. For this reason the MrkD adhesin might 
play a role in development of biofilm during an infection after all [20].  
 
To discover more about the binding of MrkD, different solutions were added to the binding assays 
to see if they would contribute to a change in the binding. Detergent was added to the assay in 
different concentration. However no change was seen in MrkD binding to the ligands (Data not 
shown). This result indicates that the MrkD binding is not due to hydrophobic interactions. If the 
binding was due to hydrophobic interactions the addition of detergent would result in a reduction in 
MrkD binding to the ligand.  
To see whether MrkD binding was due to electrostatic interactions a binding assay with different 
salt concentration was performed. The result showed decreased MrkD binding when the salt 
concentration increased (Data not shown). However it is not clear if the result is due to cell lysis 
because of the high salt concentration or it is due to the interfering of the electrostatic binding. 
Therefore it can not be concluded if the MrkD binding is due to electrostatic interactions. Others 
have suggested that the hydrophilic amino acids in MrkD are associated with the receptor-binding 
specificity, because they are most likely exposed to the surface of the adhesin while the core of the 
adhesin is hydrophobic [39]. For this reason it is more likely that the binding is due to electrostatic 
interactions than to hydrophobic interactions. 
Others have also found that MrkD binds to many different components. MrkD have been shown to 
bind e.g. tracheal epithelial cells, renal tubular cells, extracellular matrix proteins and components 
of the basement membrane in human lung tissue [3]. The common element between the ligands to 
which MrkD binding was tested were that it was damage or disrupted cells [2]. When cells are 
damage or disrupted different kind of molecules are exposed. Because of the big diversity in the 
ligands to which MrkD binds it could be hypothesized that the binding is caused by a general 
binding mechanism like electrostatic interactions.  
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When the inhibition of MrkD binding was examined it was shown that only very high 
concentrations of the inhibitors were able to inhibit the binding. Casein showed very good 
inhibitory properties towards MrkD binding. Therefore the digestion and fractionation of casein was 
started in order to identify the inhibitory fraction that could give information about the receptor of 
MrkD. However the casein also inhibited the binding of type 1 fimbria which showed that the 
inhibitory effect of casein was not specific for MrkD binding only. In addition, a fraction from 
casein has also been shown to have an inhibitory effect on Streptococcus pneumoniae and 
Haemophilus influenzae [50]. Therefore the inhibitory effect must be due to the high concentration 
of casein. 
The peptide from Synpep (SIRTDKDETTEKYHY-cys-COOH) did also have an inhibitory effect 
on MrkD binding. However there was not enough peptide to test it on the binding of type 1 fimbria. 
For this reason it is not known if the peptide was a specific inhibitor of MrkD binding. Though, 
others have found another peptide GRGDSP which has an inhibitory effect on MrkD binding to 
ileocecal epithelial cells. The effect was seen in a dose-dependent manner like with the Synpep 
peptide tested in this experiment. When they changed the peptide to GRADSP there was no 
inhibitory effect on MrkD binding [13]. The difference between the two peptides was a RGD motif 
which is a sequence found to mediate cell attachment [51]. The peptide was able to block the 
binding of MrkD to the cells because the binding affinity was greater towards the peptide. Others 
have also tried to make alterations in MrkD to see if it affected the binding. They found that 
alteration in the hot spot residue 124 and 168 in low-affinity mannan-binding MrkD, increased the 
binding to mannan [8]. These are all steps in identifying the receptor of MrkD binding, however the 
exact receptor still remain undiscovered.   
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Binding to type 1 fimbria 
  
Since the experiments showed binding of MrkD to many different ligands it was quit surprising to 
find a reduction in MrkD binding to type 1 fimbria from E. coli. As mentioned previously type 1 
fimbriae are approximately 7 nm in length and are mostly composed of the major subunit FimA to 
which the tip is attached. The tip is composed of two adaptor proteins FimG and FimF and the 
adhesin FimH [29].   
 
Further examination showed a difference in MrkD binding to different FimH variants of type 1 
fimbriae. The difference between the FimH variants was single mutations in the adhesin. One FimH 
variant (N135I_F) showed an 81 % reduction in MrkD binding while another FimH variant (G79R) 
only showed a 30 % reduction (Table 4). However the fimbria is composed of up to 1000 molecules 
of FimA but only contain 1 molecule of FimH [6, 19]. Actually over 95 % of type 1 fimbria is 
composed of the major subunit FimA [34]. Therefore the amount of FimH molecules is low 
compared to the amount of FimA molecules. For this reason the difference seen in MrkD binding to 
the FimH variants might not be due to the mutation in the FimH molecule alone, even though all the 
variants had the same FimA subunit.  
To examine whether FimH was responsible for the reduction in MrkD binding, the binding was 
tested towards pure type 1 fimbrial tips. The result showed no reduction of MrkD binding as seen 
for the FimH variants. Therefore it was concluded that the tips of type 1 fimbriae was not the reason 
for the reduction in MrkD binding. 
 
Due to the previous results it was hypothesized that FimA, the major subunit of type 1 fimbria, 
might influence MrkD binding. However the results only showed a reduction of 10-47 % in MrkD 
binding, while it was up to 81 % for the FimH variants. Still some of the FimA variants showed the 
same reduction of MrkD binding as seen for the FimH variants. Therefore it was hypothesized that 
the difference in reduction of MrkD binding might be due to the structure of the fimbria. The 
different variants of FimA could contribute to a different structure of the fimbriae which could 
influence MrkD binding. 
 
To make sure that the results was due to the different type 1 fimbria variants and not to the specific 
pili preparation that was used some of the pili was purified and tested again. The results from the 
newly purified pili showed the same as seen previously and therefore it was concluded that the 
results were reliable.  
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Structural change of type 1 fimbria 
 
To test the hypothesis regarding the structure of type 1 fimbria being the reason for the reduction in 
MrkD binding, different methods were used to change the structure of fimbria to see if it had an 
influence on the binding. 
As a beginning type 1 fimbriae were treated with boiling and with HCl/boiling. When type 1 
fimbria were treated with HCl and boiling the fimbria were depolymerized and binding of MrkD 
increased to the same level as seen to uncoated plastic. However when the fimbriae were only 
boiled the binding of MrkD was at the same level as to the native fimbriae. Type 1 fimbria is an 
extremely stabile structure and requires strong denaturing agents to dissociate [34]. Therefore 
boiling by itself is not enough to depolymerize type 1 fimbria. Then why is MrkD binding reduced 
to native type 1 fimbria when it increases when the fimbriae are depolymerized? When the fimbria 
is depolymerized it is split into many pieces, composed of the different fimbrial subunits. High level 
of MrkD binding was seen to monomeric ligands (e.g. BSA), due to depolymerization the fimbriae 
became monomeric subunits which would explain the increase in MrkD binding. It is in line with 
what others have found where the epithelial surface has to be disrupted before MrkD is able to bind 
to the cells [2, 20]. However due to the ability of MrkD to bind to uncoated plastic the wells had to 
be coated properly. Otherwise the increase seen in MrkD binding would be due to the binding to 
uncoated plastic and not to the ligand. When the coating of the wells was tested it showed that the 
depolymerized fimbriae provided better covering of the wells surfaces than the native fimbriae. 
Therefore it was concluded that the depolymerization of type 1 fimbria increased the MrkD binding.  
 
Instead of depolymerizing of type 1 fimbriae other structural changes of the fimbriae were 
examined to see the influence on MrkD binding. Glycerol and SDS were used to change the 
structure of type 1 fimbria. It was hypothesized that the tight structure of the fimbriae could be 
opened up by unraveling of the fimbria leading to a change of MrkD binding. Others have 
successfully unraveled the fimbrial structure with 50 % glycerol without destroying the fimbria 
[34]. Their procedure of glycerol treatment of the fimbria was followed. The binding of MrkD to 
glycerol treated pili was the same as to native non-treated fimbria. Therefore the fimbrial structure 
might not be responsible for the reduced binding of MrkD to type 1 fimbria. To make sure that the 
fimbriae were unraveled transmission electron microscopy (TEM) was performed on glycerol 
treated fimbriae. However the fimbria did not seem to be unraveled compared to the native fimbriae 
and the pictures of glycerol-treated fimbriae taken by others [34]. For this reason it is not certain if 
the fimbria actually has been unraveled.  
 
SDS has a denaturing effect on most protein but not on type 1 fimbria [32, 52]. When the fimbria 
was treated with SDS and SDS/boiling the binding of MrkD increased. Since SDS is a denaturing 
agent it was hypothesized that it changed the structure of the fimbriae, which led to the increase in 
MrkD binding. However SDS is a very “soapy” substance and for this reason it had to be ensured 
that the wells in the plate was coated with the SDS-treated fimbria, because MrkD is also able to 
bind to uncoated plastic. The control of the coating was made with Horse-Radish Peroxidase (HRP) 
which would bind to the empty spaces in the wells. The HRP signal was correlated with empty 
Page 66 of 78 
 
spaces in the wells which meant, that the wells were not fully covered. The results from the HRP 
assay differed between the two different type 1 fimbriae tested. The type 1 fimbria K12 showed 
better coating of the wells when treated with SDS/boiling than the type 1 fimbriae variant N135I-F. 
On the other hand both fimbriae variant showed poor coating when they were treated with SDS 
only. Therefore the increase in MrkD binding to SDS-treated fimbriae was probably due to the 
binding of MrkD to the uncoated plastic. However the type 1 fimbria K12 treated with SDS/boiling 
showed good covering of the wells. This means that the increase in MrkD binding was due to the 
SDS-treatment of the fimbria. Therefore SDS must have an influence on type 1 fimbria. However 
this was only seen for type 1 fimbria K12 and not for N135I-F which were the only two fimbria 
tested in the assay. The other type 1 fimbriae variants were not tested in the HRP assay due to 
limited time. For this reason clear conclusion of SDS influence on type 1 fimbria can not be drawn.  
However when transmission electron microscopy was performed no unraveling or change of the 
fimbrial structure was seen when treated with SDS/boiling. Therefore the SDS must have another 
influence on type 1 fimbria since an increase in MrkD binding was seen. There a least two theories 
about the influence of SDS on proteins. The first theory is that the protein can wrap itself around 
micelles of SDS and the other theory is that micelles of SDS could be formed around the protein 
[32, 33]. If the SDS is inside the fimbria it properly would not affect the binding of MrkD. However 
if SDS binds to the fimbrial surface it would contribute to a negatively charge of the fimbria. The pI 
of MrkD was predicted to be 9.18 and in solutions with pH values below point the adhesin will be 
positively charged. The experiments were performed at pH 7-7.5. Therefore MrkD would be 
positively charged in the experiments. If SDS contributes with negatively charge to the fimbria, 
electrostatic interactions between the negatively charged type 1 fimbriae and positively charged 
MrkD might be the explanation for the increase in MrkD binding to the SDS-treated fimbria.     
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Binding of MrkD to CFA/I and CS17 pili 
 
Next it would be interestingly to see if the MrkD binding would be show the same binding pattern 
to other types of pili. The binding was tested to CFA/I pili and CS17 pili.  
 
CFA/I pili are called colonization factor antigen (CFA) and CS pili are called coli surface antigen 
(CS) [38, 53]. CFA/I and CS17 pili both belong to the class 5 pili within CFA/I pili falls into 
subclass 5a and CS17 to subclass 5b [53]. Both pili binds to the small intestinal epithelial but the 
pili differ serologically from each other and are different from strain to strain [38].  
 
There are some differences between class 5 pili and class 1 pili e.g. are class 5 pili assembled in the 
“alternative” chaperone pathway, while type 1 and type 3 fimbriae which belong to class 1 pili are 
assembled in the “classical” chaperon pathway. Another difference is that CFA/I pili show 
mannose-resistant hemagglutination just like type 3 fimbria, while type 1 fimbria shows mannose-
sensitive hemagglutination [54]. 
However the pili also shares some similarities e.g. even though class 5 and class 1 pili have 
different amino acids sequences the structure and assembly mechanism is very similar. Class 5 pilus 
also resembles class 1 pilus in the way that both classes have incomplete Ig folds in the subunits 
[38]. It have also been shown that the binding of CFA/I pili becomes stronger under shear 
conditions as seen for type 1 fimbria as well [53]. The binding assay showed a high binding of 
MrkD to CFA/I pili but a low binding to CS17 pili. For this reason there must be other differences 
between CFA/I and CS17 pili which have not yet been discovered or described. However it has 
been found that the major subunit CooA of CS pili shares 53 % identity with the major subunit 
CfaB on CFA/I pili [38]. 
 
Others have found that CFA/I pili have weaker interactions between its subunits on the turn of the 
helix than P-pili which like type 1 fimbria belongs to class 1 pili. CFA/I pili have 3.17 subunits per 
turn of the helix while type 1 fimbriae have 3.0-3.3 [49, 55]. This correlates with what was seen in 
the SDS-PAGE analysis, where SDS was able to depolymerize CFA/I pili but not type 1 fimbria. 
However it has been shown that the breaking of the CFA/I pili actually helps it sustain attached to 
the epithelial cells in the gastrointestinal tract [55]. The CS17 pili were also depolymerized during 
the SDS-PAGE analysis for this reason the principle might be the same as seen for CFA/I pili.  
 
It has also been showed that both CFA/I and CS17 pili unravel at relatively low forces compared to 
type 1 fimbria. The unraveling is reversible which suggest that the pili behave in a spring-like 
manner [38]. Maybe these pili could have been unraveled by glycerol to which MrkD binding could 
have been examined, however due to limited time this was not tested.   
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Conclusion 
 
The purification of pure MrkD protein was only possible for one of the three construct (pET28a) 
examined in the thesis. However the refolding of the protein after purification was not possible.  
 
Another approach of examine the binding protperties MrkD was performed by using an E.coli 
which expressed type 3 fimbriae. The experiment showed that the MrkD adhesin binds to many 
different types of ligands. Interestingly, one ligand was found to block MrkD binding - type 1 
fimbriae from E. coli. The binding of MrkD was tested to different type 1 fimbriae variants. The 
greatest blocking in MrkD binding was seen for FimH variants of type 1 fimbriae while FimA 
variants of type 1 fimbriae only showed moderate blocking of the binding. However when the 
variants of type 1 fimbriae were depolymerized  to monomeric molecules, the binding of MrkD 
increased to the same high level as seen to uncoated plastic.  
The structure of type 1 fimbria as a factor for the blocking potency towards MrkD binding was 
examined. Glycerol has been shown to unravel type 1 fimbriae without depolymerization of the 
fimbria. In this experiment glycerol-treated type 1 fimbriae kept their blocking potency towards 
MrkD binding. However no unraveling of the glycerol-treated fimbriae was seen when examined 
with transmission electron microscopy. SDS is a denaturing agent on many proteins but not type 1 
fimbriae. SDS-treatment of type 1 fimbriae increased the binding of MrkD to the fimbriae, to the 
same level as to uncoated plastic. However transmission electron microscopy showed no structural 
change of type 1 fimbriae. SDS is negatively charged surfactant that can bind to proteins, which 
then becomes more negatively charged. The MrkD adhesin has a pI of 9.18 which mean that in 
solution with pH lower than 9.18, the adhesin will be positively charged. Due to the SDS-treatment 
of type 1 fimbriae, the fimbriae become negatively charged and therefore a sudden increase in 
MrkD binding to the fimbriae is seen. Therefore it seems that binding of MrkD is due to 
electrostatic interactions.    
To examine whether the blocking potency towards MrkD binding was unique to type 1 fimbriae, 
MrkD binding to CFA/I and CS17 pili was tested. CS17 pili showed the same blocking potency 
towards MrkD as seen for type 1 fimbria. However CFA/I pili did not block MrkD binding.  
 
In conclusion it seems that the binding of the MrkD adhesin is due to electrostatic interactions. But, 
there is still a lot that have to be investigated about MrkD and MrkD binding to identify the 
receptor. 
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Future perspectives 
 
Further work needs to be done to continue the search for the receptor of MrkD. 
 
One approach could be to make a new construct with the mrkD gene that would yield to soluble 
protein. Donor strand complementation with the chaperon mrkB might help transferring the adhesin 
to the periplasm. A C-terminal tag would not influence in signal peptide of the mrkD gene and 
thereby not affect the transfer of the protein to the periplasm. Instead of a His-tag a GST-tag could 
be used because it has shown to stabilize folding of recombinant protein.  
The purified MrkD adhesin could then be used for several experiments e.g. binding assay, 
crystallization etc.  
   
Another approach could be to examine the binding of MrkD (type 3 fimbria expressing E. coli) to 
pure amino acids. Higher binding to specific amino acids could help to identification of the 
receptor. 
  
Since different blocking potency was seen between the type 1 fimbria variants a comparison of the 
sequences could reveal information about blocking of MrkD binding and thereby provide 
information about the binding pocket of MrkD.  
 
Further examination of differences or similarities between type 1 fimbriae, CFA/I pili and CS17 pili 
could also provide information about MrkD binding because type 1 fimbriae and CS17 pili showed 
blocking potency of MrkD binding while CFA/I pili did not. Unraveling of CFA/I and CS17 pili 
with glycerol could also provide information about MrkD binding.  
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Appendix 1 
Used substrates, agar and media 
 
Solutions were generally autoclaved. Antibiotics were not added to the media before it have cooled 
down to avoid inactivation by the heat.   
Media: 
 
 
Luria-Bertani broth (LB) 
(Autoclaved) 
 
For 100 mL: 
2 tablets of LB Broth (Lennox) from Sigma 
100mL deionized water 
 
Or  
 
For 1 liter: 
10 g peptone 
5 g yeast extract 
10 NaCl 
Add to 1 liter with deionized water 
 
Or 
 
For 1 liter: 
25 g LB broth powder from Novagen 
Add to 1 liter with deionized water 
SOC 
(Autoclaved) 
 
For 1 mL: 
970 µl SOB media 
20 µl glucose (1M) 
10 µl MgSO4 (1M) 
 
Freezing media 
 
For mL: 
750 µl Beef broth 
250 µl Glycerol (87%) 
2X YT media For 1 L: 
 
16 g Bacto Tryptone 
10 g Yeast Extract 
5 g NaCl 
Add to 1 Liter with deionized water 
(Autoclave) 
 
Adjust to pH 7.0 with 5M NaOH  
Terrific Broth For 1 L: 
 
12 g Tryptone 
24 g Yeast Extract 
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4 mL Glycerol 
Add to 900 mL deniozed water 
(Autoclave) 
 
After autoclavation add 100 mL of 0.17 M 
KH2PO4 + 0.72 M K2HPO4 (dissolve 2.31g 
KH2PO4 and 12.54 g K2HPO4 in 90 mL MiliQ 
water ). Autoclave again. 
Magic MediaTM 
(Brought from manufacture) 
 
 
Plate: 
 
Content 
 
 
 
LB plate  
(Optional: with addition of antibiotic) 
 
For 100 mL: 
2 tablets of LB Broth with agar (Lennox) from 
Sigma 
100 mL deionized water 
(Autoclaved) 
 
Buffers: 
 
Contents Amount 
 
Phosphate Buffered Saline 
(PBS) 
(Autoclaved) 
 
 
NaCl 
KCl 
Na2HPO4 
KH2PO4 
For 1 L: 
 
8.0 g NaCl 
0.2 g KCl 
1.44 g Na2HPO4 
0.24 g KH2PO4 
Add 1 L deionized water 
 
PBS + BSA 
 
 
PBS 
BSA 0.2% 
For 100 mL: 
 
100 mL PBS 
2 g BSA (Bovin Serum Albumin) 
 
TBS 
 
10 mM Tris-Cl pH = 
7.5 
150 mM NaCl 
For 1 L: 
1.211 g Tris-Cl 
8.766 g NaCl 
Add 1 L MiliQ water 
 
TBS-Tween 
 
 
20 mM Tris-Cl pH = 
7.5 
500 mM NaCl 
0,05% (v/v) Tween 20 
For 1 L: 
2.422 g Tris-Cl 
29.22 g NaCl 
0.5 mL Tween 20 
Add 1 L MiliQ water 
 
3% BSA (Bovine Serum 
Albumin) in TBS 
 
 
10 mM Tris-Cl pH = 
7.5 
150 mM NaCl 
3 % BSA 
For 10 mL: 
 
 
 
0.3 g BSA 
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Add 10 mL TBS 
1X Tris-Glycine SDS running 
buffer 
 
 For 1 liter: 
 
100 mL 10x Tris-Glycine SDS running 
buffer 
900 mL deionized water 
 
 
Sonication buffer 
 
 
 
50 mM Tris pH = 8.0 
40 mM NaCl  
5 mM Betamecapto 
10 mM Imidazole 
For 1 L: 
 
25 ml 2M Tris pH = 8.0 
23.4 g NaCl 
250 µl Betamecapto (14,3 M) 
0.7 g Imidazole 
Add 1000 mL deionized water 
 
 
Wash buffer 
 
 
50 mM Tris pH = 8.0 
1 M NaCl 
5mM Betamecapto 
10mM Imidazole 
For 1 L: 
 
25 ml 2M Tris pH = 8.0 
58.44 g NaCl 
250 µl Betamecapto (14,3 M) 
0.7 g Imidazole 
Add 1000 mL deionized water 
 
 
Elution buffer AHis 
 
 
50 mM Tris pH = 8,0 
400 mM NaCl 
5 mM Betamecapto 
10 mM Imidazole 
For 1 L: 
 
25 ml 2M Tris pH = 8.0 
23.4 g NaCl 
250 µl Betamecapto (14,3 M) 
0.7 g Imidazole 
Add 1000 mL deionized water 
 
 
Elution buffer BHis 
 
 
50 mM Tris pH = 8,0 
400 mM NaCl 
5 mM Betamecapto 
500 mM Imidazole 
For 1 L: 
 
25 ml 2M Tris pH = 8,0 
23.4 g NaCl 
250 µl Betamecapto (14,3 M) 
34.04 g Imidazole 
Add 1000 mL deionized water 
 
 
EQ buffer 
 
 
Tris 20 mM 
NaCl 1 M 
For 1 L: 
 
2.423 g Tris 
11.688 g NaCl 
Add to 1000 mL deionized water 
 
 
 
Sonication buffer (inclusion 
bodies) 
 
 
 
 
 
 
 
 
 
For 1 L: 
1M stock solution: 
121.14g Tris base  
87.66 g of NaCl 
800 mL dH2O 
 
pH is adjusted to 7.41 at room 
temperature with HCl/NaOH 
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100 mM Trizma base 
150 mM NaCl 
 
1 mM EDTA 
10 mM imidiazole 
5mM Betamecapto 
Add water to 1 L 
 
For 100 mM: 
100 ml of 1 M stock solution is mixed 
with 900 ml dH2O 
 
0.292 g 
0.7 g 
250 µl 
 
Titrate to pH 7.46 at room temperature. 
Make up volume to 1000 mL 
 
 
 
Resuspension/denaturing buffer 
(inclusion bodies) 
 
 
 
100 mM Trizma base 
150 mM NaCl 
 
1 mM EDTA 
10 mM imidiazole 
5mM Betamecapto 
8 M Urea 
For 1 L: 
 
100mM:  
100 ml of 1 M stock solution is mixed 
with 900 ml dH2O 
 
0.292 g 
0.7 g 
250 µl 
480.48 g 
 
Titrate to pH 7.46 at room temperature. 
Make up volume to 1000 mL 
 
 
 
Wash buffer (inclusion bodies) 
 
 
 
100 mM Trizma base 
1 M NaCl 
 
 
 
1 mM EDTA 
10 mM imidiazole 
5mM Betamecapto 
8 M Urea 
For 1 L: 
 
100mM:  
100 ml of 1 M stock solution is mixed 
with 900 ml dH2O 
 
Add 850 mM NaCl (49.674 g) 
 
0.292 g 
0.7 g 
250 µl 
480.48 g 
 
Titrate to pH 7.46 at room temperature. 
Make up volume to 1000 mL 
 
 
 
Elution buffer (inclusion bodies) 
 
 
 
100 mM Trizma base 
150 mM NaCl 
 
1 mM EDTA 
500 mM imidiazole 
For 1 L: 
 
100mM:  
100 ml of 1 M stock solution is mixed 
with 900 ml dH2O 
 
0.292 g 
34.04 g 
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5mM Betamecapto 
8 M Urea 
250 µl 
480.48 g 
 
Titrate to pH 7.46 at room temperature. 
Make up volume to 1000 mL 
 
 
Dialysis buffer 1 (inclusion 
bodies) 
 
 
 
100 mM Trizma base 
150 mM NaCl 
 
1 mM EDTA 
5 mM Beta-mecapto 
ethanol 
1 M Urea 
For 1 L: 
 
100mM:  
100 ml of 1 M stock solution is mixed 
with 900 ml dH2O 
 
0.292 g 
250 µl 
 
60.06 g 
 
Titrate to pH 7.46 at room temperature. 
Make up volume to 1000 mL 
 
 
Dialysis buffer 2 (inclusion 
bodies) 
 
 
 
100 mM Trizma base 
150 mM NaCl 
 
1 mM EDTA 
5mM Betamecapto 
For 1 L: 
 
100mM:  
100 ml of 1 M stock solution is mixed 
with 900 ml dH2O 
 
0.292 g 
250 µl 
 
Titrate to pH 7.46 at room temperature. 
Make up volume to 1000 mL 
 
 
Bicarb buffer 
 
 
Bicarbonate 
For 500 ml: 
 
840 mg Pri Bicarbonate 
Add 500 mL MiliQ water 
 
 
Pili buffer 
 
 
150 mM NaCl 
50 mM Tris 
For 1 Liter: 
 
8.766 g 
6.057 g 
Adjust to pH 7.4 with HCl 
 
HBS-EP buffer  
(Brought from manufacture)  
 
 
10 mM Hepes 
150 mM NaCl 
3 mM EDTA 
0.005 % P20 
 
 
 
 
 
TE buffer 
 
 
10 mM Tris  
1 mM EDTA 
For 1 L: 
 
1.2114 g Tris 
0.29224 g EDTA 
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Add 1000 mL MiliQ water 
Adjust to pH 8.0 with HCl 
 
 
Antibiotics Stock concentration Dissolved in 
Kanamycin 50 mg/mL MiliQ water 
Chloramphenicol 250 mg/mL Ethanol 
Ampicillin 100 mg/mL MiliQ water 
 
 
Other solutions Contents Amount 
 
 
IPTG 
 
 
1 M IPTG 
For 1 mL: 
 
0.23831 g IPTG 
Add 1 mL MiliQ water 
 
 
Primary antibody 
solution (1:5000) 
 
 
Primary antibody  
PBS + BSA 0.2% 
For 10 mL: 
 
2 µl primary antibody 
10 mL PBS + BSA 
 
Secondary antibody 
solution (1:3000) 
 
 
Secondary antibody 
PBS + BSA 0.2% 
For 10 mL: 
 
3 µl secondary antibody 
10 mL PBS + BSA 
 
HRP solution (25µg/ml) 
 
 
 
 
HRP (10 mg/mL) 
PBS 
For 10 mL: 
 
12.5 µl HRP 
10 mL PBS 
 
TMB peroxidase reaction 
solution 
 
 
TMB peroxidase substrate 
TMB peroxidase substrate 
solution B 
For 10 mL: 
 
5 mL TMB peroxidase substrate 
5 mL TMB peroxidase substrate solution B 
 
Pierce BCA working 
solution 
 
 
BCA protein assay reagent A 
BCA protein assay reagent B 
For 10 mL: 
 
10 mL BCA protein assay reagent A 
200 µl BCA protein assay reagent B 
 
MgCl2 (2M) 
 
 
MgCl2 2M 
For 100 mL: 
 
19.04 g 
Add 100 mL MiliQ water 
 
